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CD4+ T cells play a pivotal role in orchestrating immune responses. It has now been 
shown that some cells display direct effector functioning in the elimination of viral 
infections and cancers. The T cell receptor (TCR) is thought to play a part in influencing 
these cytotoxic mechanisms and is being investigated for optimisation of TCR gene 
transfer therapies. However, with the diverse TCR repertoire available, selection of 
TCRs conferring the greatest therapeutic potential remains a challenge.    
To investigate TCRVβ usage and its effects on cellular function, in the context of the 
oncogenetic Epstein Barr Virus, we used MHC class II tetramers to isolate CD4+ T cell 
clones from healthy seropositive donor’s ex vivo, specific for the latency III EBNA2 
protein derived epitope; PRS. 
We have found that the epitope specific CD4+ T cells express TCRs with various Vβ 
usages. These T cells had a range of functional avidities for the same MHCII-epitope 
combination. We have further shown there is a direct relationship between functional 
avidity and the efficiency of a T cell clone to recognise unmanipulated LCL targets 
(EBV infected B cells).  
The results from these experiments highlight the importance of gaining further 
knowledge into the relationship between TCR usage and T cell function. This may 
provide steps towards future development of targeted MHC Class II restricted TCR 
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1.1 The Human Immune System and Cancer 
The human immune system is essential for life. Alongside its pivotal role in the 
detection and elimination of pathogenic species, the immune system is widely 
acknowledged to play a significant part in cancer prevention (Blair et al 2008). The first 
evidence of this was produced by Elie Metchnikoff and Paul Ehrlich in 1908, who 
established that the immune system could naturally recognise cancer cells as altered self 
and initiate their destruction (Tauber et al 1992).  Although these early findings were 
met with some scepticism, clinical research into cancer immunology subsequently 
developed throughout the 20th century. In the 1950s Burnet and Thomas expanded upon 
these initial findings, suggesting that the immune system was able to promote protection 
against cancer development by eliminating malignant cells before they had the 
opportunity to transform. This hypothesis later formed the concept known as cancer 
immune-surveillance (Ostrand Rosenberg et al 2008). It has now been recognized that 
in some cases, through immune-surveillance and anti-tumour responses, cancer can be 
effectively prevented and controlled. These historical research contributions have led to 
advances in the field of tumour immunology in the last 20 years, where the immune 
system has been utilised and enhanced to treat different types of cancer. Many 
successful immunotherapies exploiting both the humoral and acquired immune arms 
have now been tested in clinical trials and some are now approved for use in 




However, to develop more effective novel therapeutic strategies it is fundamental to 
understand the mechanisms underlying interactions between immune cells and tumours. 
1.1.1 The Innate Immune System 
The innate immune system is the body’s initial protection against invading pathogenic 
organisms. This primary response is rapid and involves a variety of different defence 
mechanisms, complement proteins and innate cell subtypes. After a pathogen penetrates 
through primary epithelial and mucosal barriers, they are detected by innate cells 
including macrophages, dendritic cells, granulocytes and natural killer cells, circulating 
within the infected tissue. These immune cells recognise pathogen associated molecular 
patterns (PAMPs) on the surface of invading microorganisms and danger associated 
molecular patterns (DAMPs), via membrane bound pathogen recognition receptors 
(PRRs) (Iwasaki et al 2004). This triggers both phagocytosis of pathogens and a range 
of intracellular signalling pathways the innate cells, resulting in the release of various 
signalling molecules including chemokines and cytokines along with a systematic pro-
inflammatory response (Mogensen et al 2009). Consequentially, more innate cells 
migrate to the area of infection. Dendritic cells, in particular, are essential in the 
activation of the adaptive immune response (Section 1.1.2). This is achieved through the 
processing and presentation of antigenic material on their cell surface which coordinates 
the formation of long lasting memory T lymphocytes and protection against secondary 
infections (Banchereau et al 1998).  
 
The role of the innate immune system in targeting cancer cells remains poorly 
understood. Natural killer cells (NK), primary innate immune lymphocytes, have been 




the activities of their stimulatory and inhibitory NK receptors (Liu et al 2013). 
Furthermore, the NK receptor NKG2D, which recognises the stress ligand MHC class-I-
chain-related protein A (MICA) expressed on the surface of cancer cells, stimulates the 
production of inflammatory cytokines, resulting in cancer cell apoptosis (Bauer et al 
1999). However innate immunity is not specific and is limited in tumour control. 
1.1.2 The Adaptive Immune System 
The adaptive immune system is essential for elimination and long-term protection 
against both pathogenic organisms and cancer cells. Humoral and cellular immunity are 
the two lines of adaptive defence. Adaptive immune cells also express receptors, 
however unlike the innate cells these receptors are somatically generated via gene re-
arrangements. This creates a diverse, clonally distributed receptor repertoire which is 
highly specific and enables adaptive immune cells to target specific antigens. 
Antibodies, synthesised from plasma B cells, can recognise extracellular antigens. In 
contrast, T lymphocytes discriminate foreign antigenic material from self, via T cell 
membrane bound receptors which interact with pathogen derived protein degradation 
products. Once activated adaptive immune cells initiate elimination of infected (or 
cancerous) cells and establish long lasting memory populations which are able to 
respond much more rapidly upon secondary encounter with a specific antigen. T cells 
can express either γδ and αβ T cell receptors (TCRs) (Allison et al 2002), this thesis will 
focus on the αβ TCR. 
1.1.3 T Lymphocyte Development  
To provide the most efficient cellular immune response, the T cell repertoire must be 




life. There are two types of T lymphocytes, CD8+ and CD4+ T cells, which originate 
from hematopoietic stem cells located within the bone marrow. Newly generated T cells 
migrate to the thymus, entering at the cortico-medullary junction where they initiate 
TCR rearrangements and undergo selection.  
1.1.4 TCR Generation  
To successfully produce a functional TCR and generate diversity within the TCR 
repertoire, each chain undergoes a process known as V(D)J recombination. This 
involves rearrangements of the gene segments, known as variable (V), diversity (D) and 
joining (J), to form a complete variable domain exon. V(D)J recombination is initiated 
by two proteins, RAG1 and RAG2, which together constitute the recombinase forming 
a complex which contain conserved recombination signal sequences (RSSs). These 
RSSs flank the coding sequences of individual gene segments and the formation of this 
complex allows for the joining of gene segments such as variable and joining. The 
endonuclease activity of the RAG1/2 recombinase introduces single stand DNA breaks 
within the 5’ ends of both RSSs (McBlane et al 1995). The exposed 3’ hydroxyl groups 
react with phosphodiester bonds located on the opposite DNA strand promoting the 
formation of a hairpin loop and double stand breaks within each RSS sequence (Figure 
1.1). Repair proteins Ku70:Ku80 bind to the hairpin. The nuclease enzyme; Artemis is 
recruited, phosphorylated by a DNA phosphatase kinase (DNA-PK) and opens up the 
hairpin loops (Mansilla-Soto et al 2003). The cut ends are then modified through 
random additions and deletions of non-template nucleotides, by terminal 
deoxynucleotidyl transferase (TdT), producing diversity and heterogeneity in the joint 
between the gene segments; a process known as junctional diversification. The RSSs 




essential for the re-joining steps as pairing only occurs between fragments with terminal 
12bp spacer sequences and terminal 23bp sequences (Van Gent et al 1996). DNA ligase 
IV is recruited to join the processed ends and this is followed by transcription, splicing 
of none coding segments and translation into a polypeptide sequence which constitutes 


















Figure 1.1 V(D)J Recombination. Both alpha and beta chain genes go through a 
process known as V(D)J recombination in which they rearrange gene segments to 
produce a large repertoire of TCRs for future immune responses.  (A) RAG1/2 bind to 
RSS sequences introducing single stranded DNA breaks and hairpin loop formation. (B) 
Recruitment and activation of Artemis nuclease opens hairpin loops. Followed by 
additions and deletions of nucleotides within the gene sequence (C) Recruitment of DNA 
ligase, joining of cut modified ends and transcription of newly formed gene segments 
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Allelic exclusion is another essential process of thymocyte development. This prevents 
both alleles of the same TCR chain gene, be that beta, alpha, delta or gamma chain, 
being expressed together and restricts a TCR to a single specificity. Hence, if a 
productive V(D)J gene rearrangement occurs for one beta chain gene then this promotes 
the inhibition of the other allele of that gene, preventing more than one chain being 
synthesised (Dudley et al 1994).  
Once the TCR beta chain has successfully undergone somatic gene recombination and 
allelic exclusion it will associate with an invariant pre-TCR alpha chain forming a pre-
TCR complex. This initiates alpha chain gene rearrangement and the formation of a 
double positive (DP) population of thymocytes expressing both CD4 and CD8 co-
receptors (Van De Wiele et al 2004).  DP thymocytes undergo both positive and 
negative selection checkpoints, thus ensuring only the most efficient TCRs (in terms of 
affinity) are available to induce a strong immune response.  
The development and maturation of T cells is essential for determining both their own 
TCR specificity and affinity towards a range of Peptide/MHC complexes (pMHC), 
along with preventing autoimmune reactivity towards healthy cells within the body. 
This balance is vital in maintaining an immune system robust enough to target and 








1.1.5 T Cell Receptors  
TCRs are crucial components of adaptive immune cells and a key area of interest when 
investigating the therapeutic application of T cell immune responses. Each T cell 
expresses thousands of copies of identical TCRs which target processed antigens in 
order to eliminate infection. They are further involved in cancer immunosurveillance 
strategies when interacting with tumour associated and tumour specific antigens (TAA, 
TSA) presented by malignant cancer cells. Despite the diversity of the human TCR 
repertoire remaining unknown, the gene set encoding the TCR repertoire has the 
potential to create over 1015 TCR T cell clonotypes (A population of T cells expressing 
identical TCRs) (Laydon et al 2015). 
X-Ray crystallography analysis of the αβ TCR has been paramount in furthering the 
study of its molecular structure and immune function in relation to affinity and avidity 
towards target antigens (Garcia et al 1996). The TCR is a transmembrane anchored 
heterodimer of glycoproteins consisting of distinct alpha and beta chains. These chains 
are composed of variable and constant regions bound to a hinge region, similar to that 
seen in immunoglobulins, within the humoral arm of the adaptive immune system 
(Figure 1.2). The variable domains of the TCR, which are folded into Beta sheet 
structures, contain hypervariable complementary determining regions; CDR1, CDR2, 
and CDR3. These are located on both alpha and beta chains of the TCR and 
characterised as 6 loop structures (Nielsen et al 2002).  The CDR1 and CDR2 are 
encoded within the variable gene segments of the germline. The CDR3, on the other 
hand, is predetermined by the region within both the spliced VJ Alpha and VDJ Beta 
gene segments as a result of somatic recombination events during thymocyte 




al 2017).  It is the most variable and primary region of the TCRβ locus for determining 





























Figure 1.2 Structure of αβ T cell receptor. The αβ TCR compromised of alpha and 
beta chains  both with variable and constant domains.  A stalk segment connects the 
constant region with the membrane of T cell (this contains cysteine residues forming 
disulphide bonds which stabilise each chain). CD3 complexes are located either side 
of the TCR and are essential for promoting downstream intracellular signalling after 





1.1.6 Major Histocompatibility Complexes  
Major Histocompatibility Complex molecules are encoded by human leukocyte antigen 
genes, found on chromosome 6, within the region in closest proximity with the 
chromosomal centromere. These are broadly organised into 3 separate gene loci, HLA I, 
HLA II and HLA III, encoding 3 different MHC protein molecules (Figure 1.3). The 
HLA II genes (HLADR, HLADP, and HLADQ) have been found to encode the MHC II 
molecule presented to CD4+ T cells (Ting et al 2002). Individuals contain a number of 
different HLA genes and variations of these promote a polymorphic and polygenic state. 
The entire MHC is inherited as an HLA haplotype in a Mendelian fashion from each 
parent, meaning closely related individuals such as siblings have a higher probability of 
being genotypically HLA identical (Choo et al 2007). This thesis specifically focusses 
on CD4+ αβTCR interaction with define pMHC class II complexes, as such this process 








Figure 1.3 HLA genes. HLA genes encoding MHC class I, II and III molecules 
located within the short arm of chromosome 6. Class II genes encode MHC II, class 
III genes encode proteins in the serum complement system and class I encode the 





1.1.7 MHC Class II 
The MHC II molecule, unlike the MHC I, is only expressed on the surface of antigen 
presenting cells. These include dendritic cells (DCs), B lymphocytes, monocytes, 
macrophages, and thymic epithelial cells. Notably, human T lymphocytes also express 
MHC class II molecules following activation.  The MHC II presents exogenous antigens 
to CD4+ T lymphocytes and is composed of non-covalently linked glycosylated alpha 
and beta chains, each containing 2 domains (for example, alpha 1 and alpha 2) (Figure 
1.4). The variable alpha 1 and beta 1 domains form an open-ended peptide binding 
groove which interacts with exogenous peptides, 10-15 amino acids in length.  
Hydrogen bonds form between amino acids within the binding groove and specific 
amino acids within the epitope of an antigen (Schmidt et al 2013). The exact amino acid 
and sequence the MHC molecule is composed of will determine what antigen peptides 
are able to bind. Thus, polymorphisms and altered amino acid sequences within its 
structure will modify the shape of the MHC II groove and consequentially its peptide-
binding specificity.  
1.1.8 Processing and Presentation of Exogenous Peptides by MHC Class II  
Antigenic peptides are processed and presented to naive mature CD4+ T Cells on MHC 
II molecules on the target cell via a process known as the exogenous pathway (Figure 
1.4). This involves the acquisition of antigenic peptides generated from proteolytic 
degradation in endosomal compartments from exogenous material endocytosed from the 
extracellular environment (Watts 2004).  
MHC II molecules assemble within the Endoplasmic Reticulum (ER) and associate with 




prior to MHC localization within the endo-lysosome (Cresswell et al 1996).  The 
invariable chain is released leaving behind a peptide, normally residing in its N-terminal 
region, known as the Class II associated invariant chain peptide (CLIP) that continues to 
occupy the binding groove of the MHC II. MHC-encoded heterodimeric glycoprotein 
HLA-DM then facilitates the dissociation of CLIP from the MHC II molecule. This 
promotes the formation and stabilization of exogenous pMHC class II complexes (Blum 
et al 2013) which are then transported to the cell membrane where they are presented to 















1.1.9 CD4+ T cell Activation & Differentiation   
 
 
Figure 1.4 MHC II structure and the exogenous pa hway. (A) Structure of 
the MHC Class II molecule (Murphy et al 2012). (B) Diagrammatic 
representation of the exogenous pathway deployed by MHC II in processing and 






For a CD4+ T cell to display effector or helper functions, it must interact with these 
pMHC complexes. Along with direct TCR binding and appropriate co-stimulation, 
phosphorylation of signalling domains induces various intracellular activation pathways 
involving STAT proteins which mediate transcription of genes regulating their 
differentiation status (Vahedi et al 2012). A range of CD4+ T cells subsets can be 
produced (Figure 1.5). The type of subset a naive CD4+ T cell will differentiate into is 
determined by the cytokines and co-stimulatory molecules present at the time of 
activation. There are a number of CD4+ T cells that have been defined; Th1, Th2, Th17, 
Th22, T regulatory cells (Tregs), follicular helper T cells (Tfh) and CD4+ T cells with 
cytotoxic activity (CTLs). In particular, the cells of the Th1 subset expressing T-bet 
have shown to display direct anti-viral and anti-cancer cytotoxic properties through their 
capacity to synthesise effector cytokines such as IFNγ and TNFα (Swain et al 2006). 
Despite the majority of research focussing on IFNγ producing Th1 cells, there is now 
evidence to show polyfunctional CD4+ T cell populations which produce a range of 

























Figure 1.5 CD4+ T cell subsets and functions.  Summary of the terminally 






1.2 Epstein Barr Virus (EBV)  
The Epstein Barr Virus (EBV) is a 172Kb, double stranded linear DNA, gamma 
herpesvirus that is globally prevalent. It has been shown to establish persistent infection 
in more than 90% of the adult human population (Rowe et al 2010). Infection normally 
occurs in childhood as an asymptomatic infection, however it can be delayed until 
adolescence when it can result in acute Infectious Mononucleosis (IM). This disease is 
characterised by pharyngitis, cervical lymph node enlargement, and fever along with 
abnormally high numbers of CD8+ T cells (Dummire et al 2015). In immunocompetent 
individuals, the infection is brought under control by EBV specific T cell immune 
responses.  
1.2.1 EBV Life Cycle and Infection  
Transmission of EBV is via oral salivary exchange. As illustrated in figure 1.6, the virus 
enters the lymphoid tissue and crosses the epithelial barrier where it is directed towards 
both target squamous epithelial cells and naive B lymphocytes circulating within the 
oropharynx (Williams et al 2006).  Initial interaction occurs via two viral glycoproteins, 
gp350 and gp220, which bind to the complement B cell receptor; CD21. For successful 
cell entry the activity of another viral glycoprotein complex, gp25/28 follows, 
promoting the interaction between EBV and the B cells MHC class II molecule (Taylor 
et al 2015). This mediates the activation of intracellular signalling pathways resulting in 
viral replication and release of virions as part of the virus’s lytic cycle. The EBV 
genome does not integrate into the host cell’s DNA but instead forms circular episomes 




At the same time the virus instigates a cascade of intra-nuclear events leading to the 
expression of various latency genes from the EBV viral genome, which encode 10 
proteins including six Epstein barr nuclear antigens (EBNA1, EBNA2, and EBNA3A, 
3B, 3C, and -LP), three latent membrane proteins (LMP1, LMP2A, and LMP2B) and 
BHRF1 (Price et al 2015).  The expression of this latent growth transforming 
programme is known as latency III. 
The outgrowth of the EBV infected B cell population, expressing both lytic and latent 
immunogenic antigens, is brought under control by immune responses mediated by 
CD8+ and CD4+ lymphocytes and NK cells. However, the expression of viral genes by 
some cells, within this latently infected B cell population, is downregulated inducing a 
state known as latency 0. These cells become part of a differentiated genome positive, 
but antigen negative, pool of resting memory B cells, able to circulate between the 
nasopharyngeal lymphoid system and peripheral blood indefinitely. This allows a 
degree of immune evasion and escape by the virus. At certain sites within the 
oropharynx, some latently infected B cells become permissive for the lytic infection 
cycle, releasing EBV virions into the oropharynx, which go on to infect naive B 
lymphocytes and epithelial cells or enter the saliva to be orally transmitted to other 
susceptible individuals. In this way the virus is able to remain dormant and protected 
from EBV specific immune responses, establishing persistent latent infection in 
memory B cells with occasional replication and lytic cycle entry. (Lawson et al 2001, 




















Figure 1.6 EBV life cycle. EBV initially infects epithelial cells and B 
lymphocytes within the oropharynx. Following primary infection, the outgrowth 
of lytic and latently infected b cells is controlled by an EBV specific immune 
response. EBV infected B cells switch to latency 0 in response to NK, CD4+ and 
CD8+ T-cell pressure. At certain sites lytic infection can be established from 
these latently infected B cells. This results in the release of infectious EBV 
virions which can either infect other B or epithelial cells or enter the saliva to be 
orally transmitted to other individuals. In this way a persistent infection is 





1.2.2 Immune Control of EBV  
The clinical identification of acute Infectious Mononucleosis (IM), has enabled 
researchers to investigate the EBV specific immune responses towards primary 
infection. EBV specific T cells have additionally been detected in long-term healthy 
seropositive carriers, making EBV a model system when studying the anti-viral immune 
responses occurring within humans (Rowe et al 2010). 
Adaptive immune responses towards EBV promote the latency 0 state, as infected B 
cells expressing immunogenic lytic and latent antigens are readily cleared (Taylor et al 
2015). In response to primary infection, plasma B cells are stimulated to secrete 
antibodies such as IgG. These immunoglobulins target virus capsid antigens (VCA), 
along with the EBV nuclear antigen proteins, EBNA1 and 2. Many of the antibodies 
secreted during primary infection, including IgG, are maintained throughout persistent 
infection. This has facilitated in identification of EBV seropositive carriers to be used as 
healthy donors when investigating EBV specific immune responses (Henle et al 1987). 
Along with these initial B cell responses, both CD4+ and CD8+ T lymphocytes 
proliferate, increasing in number during primary infection and IM. These cellular 
immune responses involve the interaction between the T cell receptor and pMHC 
complexes expressed by the infected B cell (Rickinson et al 2014). Most of the T cell 
expansions seen in IM patients, are CD8+ T cell driven, with large expansions occurring 
within the peripheral blood (Steven et al 1996). The majority of the immunodominant 
CD8+ T cell expansions recognise antigens associated with the lytic life cycle of the 
virus. Responses of up to 40% being specific for a single EBV epitope, derived from 




cell clones, epitopes of immediate early (IE) and some early (E) lytic cycle proteins, 
including BMLF1 and BZLF1, have also been revealed to be key targets of these CD8 T 
cell responses (Steven et al 1997, Abbots et al 2013). These findings have been 
facilitated through the use of MHC class I tetramer reagents, allowing the phenotypic 
characterisation and quantification of epitope specific CD8+ T cells. (Rickinson et al 
1997, Callan et al 1998).  A lower frequency of up to 5% of the total peripheral CD8+ 
cell population have been shown to successfully recognise some of the latency III 
proteins. These include the Epstein Barr nuclear proteins; EBNA 3A, 3B, 3C and LMP1 
which induce a cytotoxic immune response and elimination of EBV infected B cells 
(Hislop et al 2007).  
As primary EBV infection is resolved, the number of cytotoxic CD8+ T cells within the 
peripheral blood decline to a level seen in long term healthy carriers, leaving behind a 
small proportion which form the EBV specific memory CD8+ T cell pool that go on to 
control persistent chronic infection.  Once this virus specific memory pool has been 
established, the phenotypic, functional and TCR repertoire composition is stabilised and 
maintained for several years (Klarenbeek et al 2012). 
Recent technological improvements in MHC class II tetramer usage has enabled 
efficient analysis of live EBV specific CD4+ T cells, on a single cell level. Furthermore, 
this has allowed for the determination of their epitope specificity and HLA restriction 
(Long et al 2011, Long et al 2013). Despite individual epitope frequencies being much 
lower than that of CD8+ T cell responses to the same antigenic proteins during primary 
infection and IM, CD4+ T cells recognise a broader range of lytic and latent EBV 
derived peptides, meaning the antigen epitope repertoire covered is much larger (Long 




Along with their helper functions for other immune cells, research has begun to explore 
the immune responses of these less pronounced HLA class II restricted CD4+ T cells, to 
act independently of CD8+ T cells, in a direct cytotoxic manner against EBV infection. 
Effector functions are of key interest and importance to anti-viral immune responses, 
especially for viruses such as EBV that occur in cells expressing MHC II. Investigations 
into the primary differential process, along with proliferative capacity of CD4+ T cells, 
have demonstrated that these cells differentiate from naive cells into a Th1 subset of 
EBV specific CD4+ T cells, producing many common cytotoxic cytokines including 
IFNγ, TNFα and IL-2, and can induce the elimination of EBV-transformed 
lymphoblastic cell lines (LCLs) in vitro (Appay et al 2002).  However, further research 














1.2.3 EBV Associated Lymphoproliferative Diseases 
EBV contains cellular growth transforming abilities through its expression of key 
latency III genes encoding proteins which drive cellular proliferation, inducing B cell 
transformation and tumorigenesis (Table 1.1) (Kang et al 2015, Kempkes et al 2015). 






EBV latency III genes Role in B cell transformation 
EBNA1 Replication and maintenance of the episomal 
EBV genome. 
EBNA2 Transcriptional activation of B cell antigens 
and LMP1/2. Transactivation of viral C 
promotor. 
EBNA3A, B, C Transcriptional regulators which bind the host 
RBP-Jκ transcription factor supressing binding 
to cognate Jκ sequence.   
EBNA-LP Required for efficient lymphoblastic cell 
outgrowth. 
LMP1 LMP-1 is a six-span transmembrane protein 
which induces the expression of cell surface 
adhesion molecules and activation antigens 
along with driving latently infected B cells to 
leave the germline centre and become memory 
cells. 
LMP2A/B Delivers a ligand independent BCR signal 
driving both survival of resting B cells along 
with differentiation, proliferation and 
development of plasma cells secreting 
immunoglobulins. 
BHRFI This is a homologue of the anti-apoptotic 
protein Bcl-2 and an inhibitor of cellular 
apoptosis. 
BART  Encode microRNAs which facilitate long term 
persistence of the virus in an infected host. 
EBERS (EBV-Encoded RNA) These noncoding RNAs not only induce 
growth but also provide resistance to protein 




In healthy immunocompetent individuals, the development of malignancy is prevented 
by the previously described EBV specific T cell immune surveillance mechanisms. 
However, in immunosuppressed individuals, this can result in a loss of circulating virus 
specific T cells, which has been shown to increase the EBV viral load and increase the 
number of viral episomes generated within infected B cells (Thorley-Lawson et al 
2016). Consequentially, this can trigger the onset of various types of EBV associated B 
cell lymphomas including, Hodgkin’s lymphoma (HL), Burkitt’s lymphoma (BL), Post-
transplant lymphoproliferative disease (PTLD) and Diffuse Large B cell lymphoma 
(DLBCL) (Babcock et al 1999). 
The different forms of EBV associated lymphomas have different patterns of latency, 
involving the expression of differing viral genes.  Burkitt’s lymphoma is associated with 
latency type I, with EBNA-1 being highly expressed by these cancer cells. Latency type 
II has been linked to the development of HL and the epithelial derived cancer: 
nasopharyngeal carcinoma (NPC). They are characterized by the expression of latent 
genes EBNA-1, LMP-1 and LMP-2. EBVs Latency III gene profile involves the 
expression of all EBV antigens and is a key characteristic of PTLD. The action of these 
latency genes is essential for growth transformation and over proliferation of infected B 








1.2.4 EBV Positive Post-Transplant Lymphoproliferative Disease  
Post-transplant lymphoproliferative disease (PTLD) is of key interest, with EBV 
infection being associated with 90% of all PTLD cases (Gottschalk et al 2005). Being a 
heterogonous disease, PTLD presents with a diverse set of clinical symptoms and 
morphologies. This can include IM type symptoms and the development of polyclonal 
lymphoproliferative lesions. It can be divided into three categories, early lesions, 
polymorphic PTLD and monomorphic lymphomatous PTLD, with the majority of the 
latter being diffuse large B cell lymphomas (Gottschalk et al 2005). The development of 
PTLD has been linked to a deficiency in EBV specific T cell immune responses. This is 
the result of immunosuppressive drug administration to prevent graft rejection in solid 
organ transplantation (SOT), and both high dosage chemotherapy and the use of 
immunosuppressive medication, to prevent graft-vs-host disease, in allogeneic 
haematopoietic stem cell transplant (HSCT) recipients (Mansour et al 2013). Due to 
immunosuppression and functional impairment in immune surveillance, the EBV 
infection is allowed to be reactivated in seropositive individuals and results in the 
outgrowth of genetically unstable lymphoblastic B cells and clinical symptoms to 
appear. The majority of PTLD cases in SOT and HSCT patients occur within the first-
year post-transplant. Early onset PTLD has been highly associated with EBV and in 
many cases, shows high expression levels of the latency III proteins. Whereas late onset 
monomorphic cases have additionally been linked to cellular mutations in tumour 
suppressors and oncogenes such as c-Myc (Mansour et al 2013).  
The expression of latency III proteins in early onset PTLD makes this 




can be directly recognised and eliminated by infused EBV specific cytotoxic T cells 
(Gottschalk et al 2005). 
1.3 Immunotherapy for EBV Associated Cancers 
EBV related B cell malignancies, such as PTLD, can be treated with a range of 
immunotherapies due to the expression of multiple EBV latency III antigenic proteins 
and their epitopes which can be targeted specifically.  
1.3.1 Standard Therapy 
Initially, monoclonal antibody (mAb) therapies in combination with chemotherapy were 
administered to SOT and HSCT patients suffering from PTLD.  Rituximab, a mAb 
against the B cell antigen CD20 has been used extensively in patients with a high viral 
load (Oertel et al 2005). However, a significant proportion of patients fail to respond to 
this treatment, showing relapse and an increased risk of mortality. Due to this and 
limitations in relation to rituximab’s bio-distribution, modest tumoricidal activity and 
significant B lymphocytic depletion this has led to research into more effective T cell 
based immunotherapies. 
1.3.2 Adoptive T Cell Immunotherapy 
To combat the issues of standard therapies, there has been an increased interest in the 
modulation of T cells which are able to directly recognise, target and destroy cancer 
cells. The main goal of cellular adoptive immunotherapy is to utilise the 
immunomodulatory capabilities of T cells in the elimination of viral infections and 





1.3.3 Cytotoxic T Lymphocyte Infusions 
Harnessing the activity of EBV specific cytotoxic T lymphocytes (CTLs) has been 
shown to be clinically effective in treating both SOT and HSCT PTLD, even in patient’s 
refractory to monoclonal antibody-based therapies (Papaddopoulous et al 1994).  
CTLs are generated by in vitro stimulation of patient or donor PBMCs with autologous 
lymphoblastic cell lines (LCLs). LCLs are in vitro EBV transformed B cells, which 
express a full range of latent III proteins, and resemble the tumour cells that outgrow in 
PTLD. The antigen specific CTLs are then expanded and infused into patients. By 
isolating HLA matched epitope specific CTLs, this reduces the risk of GvHD.  Clinical 
success has been observed through trials utilising EBV-specific CD8+ CTLs to target 
various B cell lymphomas. EBNA3A, B, C and LMP2 specific CTL infusions have 
been used in the treatment of Hodgkin’s lymphoma, with results showing adoptively 
transferred CTLs induced complete tumour responses in some patients (Bollard et al 
2004). Furthermore, clinical trials on patients undergoing HSCT, with a high risk of 
developing B cell lymphoma, successfully showed prophylactic treatment with 
polyclonal EBV specific CTL lines and reconstituted immunity against EBV. This was 
displayed through a decrease in EBV-DNA and an expansion in viral specific immune 
activity leading to long term remission of patients (Heslop et al 2010).  
1.3.4 Therapeutic Importance of CD4+ CTLs 
CD4+ T cells are well known for their helper roles in enhancing the activity of cytotoxic 
CD8+ T cells along with their ability to be functional memory cells. There is also 
research investigating the direct effector function of cytotoxic CD4+ T cells (CD4+ 




immune cells to be used to control EBV induced B cell malignancies such as PTLD, 
where the tumour cells present antigens via MHC class II.   
CD4 CTLs have been shown to be most closely related to the Th1 subset in terms of 
transcription factor differentiation regulation and cytokine production (Takeuchi et al 
2017). The cytotoxic effects of these cells have been associated with various previously 
established CD8+ mechanisms including Fas-FasL interactions, the perforin/granzyme 
pathway, and granulysin release (Appay et al 2002). During differentiation and 
expansion, CD4+ CTLs are able to lose the expression of co-stimulatory molecules such 
as CD28 and CD27. In doing so, they gain the expression of various cytotoxic granular 
proteins including granzymes and perforin, along with memory markers such as 
CD45RO and the activation marker CD69, associated with cytotoxic functioning. These 
are seen similarly in antigen experienced CD8+ T cell development. Thus, CD4+ CTLs 
gain the cytotoxic phenotypic features used to target and eliminate virally infected 
cancer cells (Appay et al 2002, Vanhoutte et al 2009). 
In the context of EBV, in vitro studies have demonstrated the direct cytotoxic capacity 
of isolated and cultured EBV specific CD4+ T cells. These cells can directly lyse 
epitope loaded LCL targets and inhibit their outgrowth, in vitro (Münz et al 2000, Long 
et al 2005, Taylor et al 2006).  
The importance of EBV specific CD4+ T cells in adoptive immunotherapy has been 
exemplified in clinical trials, using 3rd party cytotoxic CTLs generated from HLA-
matched allogenic EBV-seropositive donors, to treat patients with SOT PTLD. All CTL 
infusions, contained populations of both CD8+ and CD4+ T cells. From 33 patients 




patients receiving CTL infusions, that comprised of a greater proportion of CD4+ T 
cells. This trend was successfully maintained at 6 months after the first infusion with a 
total response rate of 52% and no long term off target adverse effects observed (Haque 
et al 2007). This demonstrates the importance of CD4+ T cells in providing help to 
CD8+ cytotoxic T cells. Whether CD4+ cells within CTL infusions are helper or direct 
effector cells is still unknown, however it does provide a starting point for future 
alternative approaches for the treatment of various viral infections and cancers. 
There are now a growing number of third party donor derived EBV specific CTL cell 
banks that have been manufactured both within the UK and USA, showing to offer an 
effective curative strategy for the treatment of EBV associated lymphomas (Leen et al 
2013) (Vickers et al 2014). Although this adoptive immunotherapy has shown some 
success in EBV+ lymphoma patients, previously failing to respond to standard 
therapies, there are various constraints surrounding this therapeutic approach. Forth 
most, in vitro generation of donor derived EBV specific CTLs and target EBV 
transformed B cell lines takes 40-60 days to complete, and a further 28-35 days of 
expansion and elimination of alloreactive T cells (O’Reilly et al 2016). With CD4+ T 
cells being much lower in frequency within donor blood this can additionally result in a 
poor yield of virus specific CTLs being obtained. Furthermore, the final CTL 
population produced has to be patient specific with regards to screening for HLA allele 
matches. For this to be most therapeutically efficient, it requires the identification of an 
individual matched allele that also confers antiviral activity against the infecting virus in 
both donor and recipient. This has led to investigations into other novel methods, such 





1.3.5 TCR Based Therapies-TCR Gene Transfer  
The limitations surrounding adoptive transfer of EBV specific CTLs, has led to 
exploration of the T cell receptor molecule and its therapeutic relevance in adoptive T 
cell- based transfer applications.  
Research has begun investigating TCR gene transfer as a therapeutic approach to target 
many forms of cancers, this holds great therapeutic potential. Theoretically the T cells 
being subject to this gene transfer approach could be engineered to respond to virtually 
any tumour specific antigen. Currently the identification of candidate TCRs involves the 
isolation of tumour specific T cell clones. Genes encoding both the alpha and beta 
chains of the TCR can be identified and sequenced on a single cell basis. These are 
inserted into retroviral or lentiviral vectors and transferred into T cells, allowing for the 
rapid generation of antigen specific T cell populations. Currently, genetically transferred 
TCRs are being used to treat several forms of advance stage cancer directed against both 
tumour and viral antigens. Many of these have shown some degree of clinical success in 
terms of direct killing capacity by the genetically modified T cells (Rapoport et al 2015, 
Yao et al 2016). 
Identifying antigen targets which are shared amongst many patients, presented through 
the same HLA allele, expressed explicitly on tumour cells and are highly immunogenic 
is key to success. This forms the basis for the safety and efficiency of TCR based gene 
therapy, however it still remains a significant challenge. The majority of TCRs 
clinically tested previously have been directed against tumour associated antigens 
(TAAs) such as the melanoma associated antigens; MART1 and gp100, and the 




nonmutated self-proteins selectively expressed or overexpressed on cancers cells 
(Johnson et al 2009). Unfortunately targeting TAAs has resulted in on-target toxicity 
with normal tissue expressing low levels of a target antigen (Bendle et al 2010).  
Exploration into virus specific antigens associated with cancer development has enabled 
some of these previous challenges to be overcome in a subset of cancers derived 
specifically from viral infections. Cancers associated with transforming viruses, express 
viral protein products which are attractive antigen targets for TCR gene therapies, as 
they are not expressed by normal healthy cells.  
With regard to TCR gene transfer therapy for EBV associated malignancies, this is a 
useful system as the antigens expressed on infected B lymphoblast’s are truly foreign 
meaning off-target adverse effects are less likely to occur. Work conducted by Jurgans 
and colleagues demonstrated the transferal of HLA-A2, A23, and A24 restricted TCRs, 
derived from human CD8+ CTL clones led to a strong immune response and cellular 
lysis of target LCLs presenting the latency III protein LMP2, in vitro (Jurgans et al 
2006). More recent studies have shown clinical success in the treatment of 
nasopharyngeal carcinoma, using LMP2 specific TCRs restricted though HLA A11, 
with robust antigen specific function being observed in transduced CD8+ CTLs (Zheng 
et al 2015). However, in the context CD4+ TCR gene transfer, little is known regarding 
therapeutic potential and to date there has been no development of an MHC class II 






1.4 TCR Repertoire Analysis  
The adaptive immune system generates a significant diversity of unique antigen specific 
TCRs due to V-D-J gene segment recombination events which occur during T cell 
development (Section 1.1.4). Following thymic selection, this process results in the 
formation of a vast αβTCR repertoire, however the number of different clonotypes 
expressed by the estimated 1012 T cells within the human body is still unknown (Arstila 
et al 1999).  TCR selection for gene transfer therapies remains a challenge due to the 
broad TCR repertoire available. Recent in-depth analysis of the TCR repertoire of 
antigen specific T cell immune responses, however, has meant the most therapeutically 
relevant TCRs within an epitope specific population could be selected for in the future. 
Advances in high throughput DNA sequencing has led to the determination of hundreds 
of thousands of CDR3 sequences, defining phenotypes and subsets of T cell clonal 
populations, and their TCR repertoire usage responding most significantly to single 
peptide epitopes (Wang et al 2010, Warren et al 2011). This has allowed for the 
comparison of individual T cell clones and their frequency in a given population of 
antigen specific T cells. 
Recent studies have attempted to determine the immune TCR repertoire status under 
different disease statuses, including viral infection and cancers, selected for by specific 
peptide antigens. Work conducted by InYoung Song et al, investigating immune 
responses towards the influenza A M1 epitope in HLA-A2+ healthy individuals, 
demonstrated that epitope specific CD8 T cell populations express a broad repertoire of 
differing TCRs specific for the same pMHC complex. Most donors were found to have 




memory pools.  However, a single public TCR beta variable (TRBV) gene segment, 
TRBV19, associated with a few specific CDR3 motifs, did appear to dominate 65% of 
the overall CD8+ T cell response to the M1 epitope (InYoung Song et al 2017).  Point 
mutations within the TRBV19 gene, during early recombination events, will have 
promoted the production of these differing CDR3 motifs. This highlights the importance 
of structural similarities in peptide specific T cell populations responding to the same 
epitope. Further analysis of anti-viral T cell immune responses has utilised mass 
spectrometry, multiplex tetramer and antibody staining to quantify and phenotypically 
characterise multiple antigen specific CD8+ and CD4+ T cells at a single cell level 
within infected murine models (Fehlings et al 2018). The broad combination of 
phenotypic markers detected emphasises the diversity available during antigen specific 
immune responses.  
The combination of both conserved and diverse structural and phenotypic components 
of an antigen specific TCR repertoire could be influential in preventing individual 
clonotypic loss. This has been shown to contribute to the maintenance of repertoire 
diversity and overall memory effector T cell pool generation. 
With regards to CD4+ T cells although antigen specific CD4+ TCR repertoire usage is 
less well defined, it has been identified that antigen specific T cell populations can 
display differences in recognition of single peptides based on differences in their TCR 
contact residues located within the epitope peptide (Pu et al 2002).   
To date, the only work attempting to investigate the relationship between TCR sequence 
and function of T cells, at a single cell level, was conducted by Han and colleagues. 




genes along with in vitro phenotypic analysis of transcription factors conferring 
function, in relation to subset differentiation, within single antigen specific T cells (Han 
et al 2014). This provided some suggestion that different TCRs activate antigen specific 
T cells differently increasing the diversity of differentiated effector memory T cell 
pools. 
In the context of EBV infection and the TCRVβ usage during immune responses, early 
studies demonstrated that identical Vβ gene sequences were positively expressed by 
different CD8+ T cell clones in response to EBNA3 antigen epitopes, FLRGRAYGL 
(FLR) and QAKWRLQTL (QAK) (Burrows et al 1995). Thus, despite an enormous 
repertoire, it was shown that responses, could be conserved to a single TCRVβ sequence 
within the same healthy individual or separate HLA matched people.  
More recently, the availability of large panels of monoclonal antibodies to TCRs, 
mainly against Vβ epitopes, has enabled the analysis of the TCR repertoire of an epitope 
specific population via flow cytometry. Using this technology, it has been shown within 
our laboratory that in healthy EBV seropositive donors epitope-specific CD4+ T cell 
populations can comprise T cells expressing multiple TCRs, however, there is often an 
over-representation of single Vβ chain usage (Figure 1.7).   
These findings provide some indication that there is a form of precise TCRVβ repertoire 
usage in antigen specific immune responses, towards single EBV peptide epitopes, that 
may provide a structural/functional advantage for TCR recognition. However, in spite 
of this previous TCRVβ repertoire analysis, much less is known regarding the 
































Figure 1.7 Clonogram of TCRvβ repertoire usage in EBV antigen specific CD4+ T 
cell populations.  In tetramer positive T cell populations (red) there is an increased 








1.5 The Relationship between TCR Usage and T cell function  
The use of immunodominant TCRs which promote optimal anti-viral and anti-tumour 
activity have been proposed to enhance the effectiveness of gene-modified T 
lymphocytes. Research investigating the different TCR properties that confer the most 
efficient immune responses is thus essential for further improvements in TCR gene 
transfer therapy.  
The parameters used to describe the ability of T cells to recognize and respond to target 
antigens include TCR affinity, and functional avidity. TCR affinity refers to the 
physical strength of monomeric interactions between TCRs and pMHC complexes 
(Vigano et al 2012).  In immune responses these interactions are generally of low 
affinity, which makes it difficult to determine relationships between initial binding 
parameters and T cell function. However, assessment of the strength of these 
interactions has shown a slower MHC dissociation rate during TCR binding leads to a 
better T cell immune response (Holler et al 2003). T cell activation remains critically 
dependent on this functional parameter. Through optimising structural components 
within an introduced TCR, it is thought this could lead to an increase in TCR surface 
expression and improve the efficiency of TCR gene transfer therapies. Enhancing the 
TCR affinity through in vitro maturation, has been associated with more efficient 
immune responses in transferred T cells (Thomas et al 2011). However, defining the 
optimal affinity threshold between anti-tumour and autoimmune activity is essential to 
prevent adverse cross-reactivity effects seen previously in many in vitro enhanced 




Initial TCR binding interactions have been associated with influencing the functional 
avidity of a T cell. Functional avidity is defined as the biological measure of the ex vivo 
response produced by a T cell to a given concentration of target peptide and comprises 
the efficacy and sensitivity of recognition and the cellular response. 
Biological responses include proliferative capacity, cytokine production and cytotoxic 
activity of a responding cell. Antigen specific T cells producing the best responses to 
target cells presenting a lower density of peptide, are considered to be high avidity. In 
the context of the HIV virus, it has been shown in vitro that epitope specific CTLs 
exhibiting high functional avidity can mediate a robust immune response and superior 
control of viral replication (Almeida et al 2007).   
The relationship between the functional parameters of a T cell and its TCR usage has 
not been explored in depth, ex vivo. This is important to study, as the identification of 
those antigen specific T cell populations exhibiting the most efficient anti-viral and anti-
cancer immune responses is essential for the future optimisation and development of 
effective TCR gene transfer immunotherapies. For CD4+ T cells, this is especially true 
for malignancies expressing antigens through MHC class II, such as EBV associated 
PTLD. 
1.6 EBNA2 Model 
This project addressed these issues focusing on an epitope derived from the EBV 
latency III protein, EBNA2. This antigenic protein is one of the first to be expressed by 
infected cells and is important in B lymphocytic transformation, as it drives the 
expression of other crucial viral and cellular genes. It has been shown to directly 




oncogenes such C-Myc previously associated with unregulated cellular over-
proliferation (Young et al 2003, Kim et al 2016). 
Despite the evidence of its oncogenetic functioning, EBNA2 is still yet to be explored in 
depth as a therapeutic biomarker for immunological based treatments. Due to its high 
levels of immunogenicity in most people infected and presentation of epitopes on MHC 
class II molecules by infected lymphoblast’s, this makes it an ideal antigen target for 
cytotoxic CD4+ T cell immune responses and EBV specific TCR gene transfer 
immunotherapies (Khanna et al 1997). The previous determination of many epitopes 
within EBNA2 combined with development and optimisation of EBNA2 MHC II 
tetramer reagents, makes it a useful model when investigating epitope specific T cell 
populations, ex vivo.  
Therefore, we explored the EBNA2 epitope; PRS which has been shown to elicit strong 
cytotoxic CD4+ immune responses in the context of several different HLA class II 
alleles (Long et al 2005). PRS specific CD4+ T cell clones have now been successfully 
generated which have the capacity to directly recognise LCL target, along with the 
ability to eliminate their outgrowth, in vitro. (Long et al 2005). The EBNA2 epitope 
PRS, is thus an ideal epitope target for analysing the relationship between TCRVβ 








 1.7 Aims of the Project  
We hypothesised that TCR usage may affect T cell function, making some TCRs of 
greater therapeutic benefit than others. 
The project aims were therefore: 
(i) To isolate a panel of PRS specific CD4+ T-cell clones from 2 healthy HLA 
matched EBV seropositive donor by, ex vivo MHCII tetramer selection.  
(ii) To analyse the TCRVβ repertoire usage of the epitope specific CD4 T cell 
clones, using flow cytometry. 
(iii) To investigate the function of the PRS-specific T cell clones with known Vβ 
usage, through assessing their functional avidity, and the ability of the clones 















2. MATERIALS & METHODS 
 
2.1 Ethics Statement and Donors 
All blood samples used were obtained from healthy laboratory volunteers who provided 
written informed consent to participate in the project. Apheresis were provided by 
Birmingham NHS Blood transport. All experiments were in concordance with the 
University of Birmingham and South Birmingham LREC (14/WM/1245). 
2.2 Isolation of Peripheral Blood Mononuclear Cells 
Peripheral blood mononuclear cells (PBMCs) were obtained from heparinized venous 
blood of HLA-DR7+ seropositive healthy donors, and separated by Ficoll-Paque 
centrifugation. 30ml of Peripheral blood was combined with plain RPMI 1640 medium 
at a 1:1 ratio and layered on Ficoll-Paque; a density gradient media used to separate 
mononuclear cells from whole blood. Following centrifugation at 1800rpm for 30 
minutes (no brake) at room temperature, PBMCs were extracted from the 
mononuclear/lymphocyte cell layer at the plasma-Ficoll interface using a clean transfer 
pipette. PBMC were washed 3 times in RPMI 1640 medium and resuspended at 1x106 








2.3 Generation of EBV Specific T cell clones 
2.3.1 Isolation of PRS Specific CD4+ T Cells by MHC Class II Tetramer Staining 
and Fluorescent Activated Cell Sorting 
CD4+ T cells were negatively isolated from PBMCs (Section 2.2) utilising a Dynabeads 
isolation kit. The isolated cells were re-suspended in 1ml of Human serum, centrifuged 
(1600 rpm for 5 minutes) and incubated for 1 hour with 1μl of HLADR7/PRS tetramer 
complex conjugated to PE, to reactivate tetramer specific CD4+ T-cells. The cells were 
then washed with MACs buffer to remove any unbound HLA class II tetramer/peptide 
complex and stained for CD3+ and CD4+ surface markers for 20 minutes in darkness. 
Appropriate compensation tubes were prepared including anti-CD3 APC, anti-CD4 
ECD and anti-CD4 PE for tetramer positive cell populations. The cells were fluorescent 
activated cell sorted (FACS) in order to obtain frequencies of tetramer positive CD4+ T 
Cell populations from each healthy donor. 
2.3.2 Limiting Dilution Cloning 
Clones were established by seeding tetramer positive CD4+ T cells (Section 2.3.1) at 
0.3, 3 and 10 cells/well into round bottom wells of ninety-six well culture plates. This 
method increased the likelihood of obtaining a monoclonal daughter cell population 
derived from a single T cell, from this initial polyclonal mass of CD4+ cells. Irradiated 
autologous HLA-matched LCL cells (105/well) and feeder cells (106/well) were added 
to the tetramer positive CD4+ T cells along with Human Serum and RPMI 
supplemented with a Pen/Strep antibiotic mix (CD4+ Cloning mixture). The HLA–
matched LCLs were pulsed with cognate PRS peptide (Table 2.2) for 1 hour prior to co-




from 3 pooled fresh buffy coats, which had been previously exposed to 
phytohemagglutinin (PHA) at 10μg/ml for one hour, and then washed twice in standard 
media (Table 2.1). Both the PHA treated and peptide pulsed autologous HLA-matched 
LCLs were γ-irradiated at 4000 rads and washed twice before use. The seeded cells 
were left for 2 weeks and screened for peptide specificity as described below (2.6.2).  
Any epitope specific clonal populations were expanded further via transfer into 24 well 
plates, with 105 LCL cells/well and 106 feeder cells/well, kept in 5% CO2 and at 370C. 
2.3.3 Maintenance of T cell clones  
The T cell clones were maintained in  T Cell media (Table 2.1), fed twice weekly and 
split into new wells when proliferation confluence was apparent. If growth rate was 
poor, re-stimulation was performed which involved the addition of irradiated (4000 
rads) LCLs and PHA treated feeder cells. 
2.4 Generation and Culture of Lymphoblastic Cell Lines (LCL) 
 LCLs were generated in vitro from donor PBMC derived B lymphocytes with the use 
of the marmoset B59.8 producer. LCLs were obtained by centrifugation of 4mls of 
B59.8 supernatant which was filtered through a 0.45μm syringe and incubated overnight 
at 370C 5% CO2. The next day the PBMCs were centrifuged and resuspended in 2ml of 
standard culture media supplemented with 1μg/ml cyclosporine A for a period of two 
weeks in a 24 well plate. Cells were split once sufficient proliferation had occurred. All 
LCL lines were maintained in standard media.  The LCLs used in this project were 
either generated specifically for these experiments or previously had been made and 





2.5 Cryopreservation and Restoration of Cells 
Cryopreservation involved centrifugation of cells (LCL and T cells) at 1600rpm for 5 
minutes. The cells were resuspended in freezing media (Table 2.1) and transferred to a 
sterile 1ml cryovials. These were then transferred to a Mr. frosty containers holding 
isopropanol which was placed into a -80°C freezer.  
Restoration of cells began with removal from of cryovials -800C freezers and transferal 
into a water bath heated to 37°C. Post thawing, the cells were resuspended in relevant 
culture media dropwise and washed twice via centrifugation at 1600rpm for 5 minutes 
in order to remove freezing media. Cells were then either used in experimental analysis 
or transferred to a 24 well plate and incubated at 37°C and 5% CO2. 
2.6 Functional Analysis of T cell clones 
2.6.1 IFNγ ELISA 
IFNγ ELISA was performed to measure many factors of functionality of the T cell 
clones. Ninety-six well ELISA plates were pre-coated with anti-IFNγ monoclonal 
antibody (MAb) and left overnight at 40C. The next day the plates were blocked for 1 
hour with blocking buffer (Table 2.1) to prevent any non-specific binding. Following 
washing the plates with PBS buffer (Table 2.1), 50μl of supernatant from the T cell 
clone/LCL mixtures being tested (Sections 2.6.2, 2.6.3 and 2.6.4) was added along with 
IFNγ standards into separate wells, and left for 3-4 hours at room temperature. 
Standards were made by double dilutions of IFNγ from 20,000 pg/ml to 0pg/ml in 
standard media. This incubation was followed by another PBS wash and the addition of 
50μl of biotinylated anti-IFN-γ MAb to each well which was incubated at room 




washing, and replaced with 50μl of streptavidin horseradish peroxidase to each well, left 
to incubate for an additional 30 minutes. After a final wash, 100μl of TMB (3,3',5,5'-
tetramethylbenzidine) soluble substrate was added to each well and yielded a blue 
reaction product. The reaction was stopped after a period of 20 minutes with the 
addition of 100μl 1M Hydrochloric acid. The amount of IFNγ produced by each clone 
was analysed using a MPM6 exe plate reader and excel software package measuring 
A450. IFNγ release was calculated by comparing A450 from T cell clones against a 
standard curve.  
2.6.2 Screening Polyclonal T Cell Populations for Peptide Specificity  
50µl of each isolated CD4 T cell clonal culture was incubated overnight in V bottom 
micro test plate wells with HLA II matched LCL target cells (50,000 cell/well), media 
and PRS peptide (Table 2.2). The HLADR7 matched LCLs were either un-manipulated, 
or pre-exposed for 1h to 5μl of PRS epitope peptide. The clones were additionally tested 
with media alone and media combined with 10μg/ml peptide. After overnight 
incubation the test supernatant medium from the T cell and LCL co-cultures was 
assayed for IFNγ production by the previously described ELISA method (Section 
2.6.1). A positive result was higher IFNγ production from the LCL/peptide compared 
with LCL alone and media/peptide compared to media alone. 
2.6.3 Peptide Titration Assays  
The functional avidities of T cell clones were similarly tested in ELISA assays of IFNγ 
release, against titrated concentrations of individual defined PRS peptide epitope 
presented by autologous HLA-matched LCL targets. Equivalent volumes of LCL media 




clones (100μl/well) were added to triplicate wells at known cell numbers 
(2000cells/well) in the presence of 80μl HLA matched LCL targets (50,000cells/well) 
and 20μl PRS peptide epitope at dilution range of 1x10-5 to 1x10-11 M (including no 
peptide). The plates were incubated overnight at 37°C in 5% CO2. The supernatant 
medium from the T cell and LCL co-cultures was harvested after 12-16 hours and 
assayed for IFNγ by ELISA (Section 2.6.1). 
2.6.4 LCL Recognition Assays  
Individual T cell clones were incubated in v bottom micro test plate wells with 50,000 
autologous HLADR7 matched or HLA mismatched LCL (100μl/well). This was 
performed in triplicates. The LCLs were either un-manipulated or pre-pulsed with 5μl 
of exogenous PRS peptide epitope for 1 hour and then washed with standard media. 
These were co-cultured with 100, 500, 1000 or 5000 cells of a given T cell clone at 
370C 5% CO2. LCL and T cell controls were included in separate wells in which they 
were incubated with standard media alone.  The supernatant was harvested after 12-16h 
and an ELISA assay measuring IFNγ was performed (Section 2.6.1). 
2.7 TCRVβ Analysis of PRS Responsive T cell clones 
2.7.1 T cell TCRVβ Usage Analysis 
From each donor, PRS specific CD4+ T cell clones, were analysed in order to 
phenotypically characterise their TCRVβ expression and specificities.  A matrix of 
pools of T cell clones for each donor was constructed. Each pool within this matrix, 
contained 6 clones (Donor 1) or 5 clones (Donor 2) and each clone was present in 2 
different pools. This analysis was performed using an IOTest Beta Mark TCR 




(Beckman Coulter).  The kit contained 8 vials of mixtures of conjugated TCRVβ 
antibody complexes; A to H, each composed of 3 separate TCRVβ antibodies labelled 
with fluorescein isothiocyanate (FITC), phycoerythrin (PE) or doubly labelled with 
FITC and PE (Table 2.3). These antibody complexes corresponded to 24 different Vβ 
subfamilies. 
T cell clones for a given pool were counted and a volume to obtain 700,000 cells 
(70,000cell/tube x 10 tubes) was extracted and dispensed into a 15ml tube. Once this 
was completed for all clones within a pool the volume within the 15ml tube was made 
up to 10ml with MACs buffer and distributed evenly between 10 FACS tubes; 1ml per 
tube. These were made up of an unstained sample, anti-CD3/CD4 gating antibodies 
only stained sample, along with the 8 TCRVβ antibody stained samples (A-H). An 
additional 1ml of MACs buffer was added to all tubes and each sample was centrifuged 
at 1600rpm for 5 minutes. Following centrifugation, 1μl of Viability Dye was added to 
relevant tubes and incubated at 40C for 30 minutes. The samples were washed and 
stained with 1μl of both APC conjugated anti-CD3 and ECD or PE-Cy7 conjugated 
anti-CD4 gating antibodies followed by 5μl of the relevant TCRVβ antibody complexes 
from the IOTest Beta Mark TCR Repertoire staining kit (Table 2.3). The cells were 
incubated at room temperature for 30 minutes followed by a final wash and 
resuspension in 250μl of MACs buffer prior to LSRII flow cytometer analysis.   
Along with the test samples, compensation samples were additionally set up to 
compensate for fluorochrome overlap. This included; 1μl of APC-Cy7 conjugated anti-
CD14, 1μl of APC conjugated anti-CD3, 1μl of ECD or PE-Cy7 conjugated anti-CD4, 
2μl of PE conjugated anti-CD4 and 2μl of FITC conjugated anti-CD4.  Compensation 




added in relevant volumes. The samples were then analysed via flow cytometry using 
the LSRII; 20,000 events were recorded for each sample. The samples being tested and 
unstained control were gated on forward (FSC) and side scatter (SSC) after which any 
doublets and dead cells were excluded and CD3+ CD4+ T lymphocytes were gated on 
specifically. The data was then further analysed on Kaluza software. Confirmation of 
TCRVβ expression on individual clones was achieved through; the use of 7μl single 
conjugated TCRVβ antibodies (Table 2.4).  
2.8 TCR Profiling  
Certain T cell clones with known TCRVβ usage and displaying interesting results from 
functional analysis were further investigated via sequencing of both their alpha and beta 
chains. 
2.8.1 RNA Extraction and 5’-RACE-Ready cDNA Formation from T Cell Clones 
RNA was extracted from PRS specific T-cell clonal cell pellets of 5x105 cells following 
the RNeasy plus microkit protocol, as per the manufacturer’s instructions (Qiagen). 
RNA concentration was then measured using a Nanodrop microvolume 
spectrophotometer in ng/μl. Following RNA extraction, 5’ and 3’ RACE Ready cDNA 
was synthesised via reverse transcription of the eluted RNA utilising a SMARTer II A 
oligonucleotide primer and SMARTScribe reverse transcriptase, as per the 
manufacturer’s instructions (Qiagen). This provided a 5’ anchor for subsequent PCR 






2.8.2 Rapid Amplification of cDNA ends (RACE)  
PCR 5’-3’ RACE reactions were performed on the synthesised 5’ RACE Ready cDNA 
samples (Section 2.8.1) to generate 5’ and 3’ cDNA fragments.  This used gene specific 
primers for both the alpha and beta chains of the clones TCR. PCR cycling parameters 
included; 5 cycles at 94 degrees for 30 seconds, 72 degrees for 3 minutes. 5 cycles at 94 
degrees for 30 seconds, 70 degrees for 30 seconds, 72 degrees for 3 minutes. 20 cycles 
of 94 degrees for 30 seconds, 68 degrees for 30 seconds, and 72 degrees for 3 minutes. 
These cycles of denaturation, annealing and extension were performed utilising a PCR 
system.   
2.8.3 Characterisation of RACE Products  
Agarose gel electrophoresis was performed on the RACE PCR DNA products (Section 
2.8.2). This included negative controls for each TCR alpha and beta chain. Gel images 
were obtained using a UV-image analyser and bands of the correct size (200bp) were 
cut out. DNA of interest was recovered and purified using a gel extraction spin column 
method kit as per manufacturer instructions (Qiagen). DNA concentration was 
measured using a Nanodrop microvolume spectrophotometer in ng/μl. 
2.9.4 DNA Sequencing  
11μl of reaction mixture containing 4ng of the recovered and purified DNA (Section 
2.9.3) and relevant alpha or beta primers were sent to the University of Birmingham 






2.9 Tables of Reagents  
Reagents and Medias Ingredients 
Standard Media RPMI 1640 media (Sigma) supplemented 
with 100 IU/ml penicillin (Gibco), 100 
μg/ml streptomycin (Gibco) and 10% Fetal 
bovine serum (FBS). 
T Cell Media RPMI 1640 media (Sigma) supplemented 
with 100 IU/ml penicillin (Gibco), 100 
μg/ml streptomycin (Gibco), 10% Fetal Calf 
Serum (BioSera), 1% Human serum (TCS 
Biosciences), 30% Monkey Leukocyte 
Antigen 144 (MLA 144) cell line and 
50ug/ml interleukin 2. 
 
CD4 T Cell Cloning Media Standard culture media supplemented with 
1% HuS, 50U/ml IL2 and 30% filtered 
supernatant harvested from the Monkey 
Leukocyte Antigen 144 (MLA 144) cell 
line. 
 
Cyclosporine A Media Standard culture media supplemented with 
cyclosporine A (1ug/ml). 
Freezing Media RPMI 1640 containing 2mM L-glutamine, 
20% FBS and 10% DMSO. 
Coating Buffer 10x stock solution was made of 1.36g 
Sodium Carbonate (Sigma), 7.35g 
Potassium Bicarbonate (Sigma) and 100ml 
sterile H2O. The buffer was adjusted to 




Blocking Buffer 1 1xPBS tablet (Thermo Scientific) was 
added to 500ml of sterile H20. To this 5g of 
Bovine serum albumin (BSA) (Sigma) and 
250ul of tween (Sigma) was added. 
Phosphate Buffer Saline (PBS) Wash 
Buffer  
10 1x PBS tablets (Thermo Scientific) was 
added to 5Litres of sterile H20 and 2.5ml of 
tween (Sigma) was then added. 
MACs Buffer 0.5% Bovine Serum Albumin (BSA) and 
2.5mM Ethylenediaminetetraacetic acid 
(EDTA) was added to PBS. 
 











EBNA2 276-295 (PRS)TVFYNIPPMPLPPSQL DRB1*07 
(DR7) 
Table 2.2. Summary of HLA-allele EBV epitope combination 
 
2.10 Tables of Antibodies  




Beckman Coulter TCRVβ 
antibody complexes: 
Vβ: Conjugated Fluorochrome: 
A Vβ 5.3 


















































Table 2.4.  Individual TCRVβ antibodies for staining of T cell clones 
 











TCRVβ antibody Source Clone Volume used 
per sample 
PE conjugated anti-vβ1 Beckman  Coulter BL37.2 7ul 
FITC conjugated anti-vβ2 Beckman  Coulter MPB2D5 7ul  
FITC conjugated anti-vβ5.1 Beckman  Coulter IMMU 157 7ul  
PE conjugated anti- vβ17 Beckman  Coulter E17.5F3.15.13 7ul  
FITC conjugated anti-
vβ21.3 
Beckman  Coulter IG125 7ul  
Antibody Source Clone Amount used 
APC conjugated anti-
human CD3 
Invitrogen  7D6 1µl 
PE Cy7 conjugated 
anti-human CD4 
BD Biosciences RPA-T4 1µl 
ECD conjugated anti-
CD4  
Beckman Coulter SFCI12T4D11 1µl 
PE conjugated anti-
human CD4 
BD Biosciences RPA-T4 2µl 
FITC conjugated anti- 
human CD4 
BD Biosciences RPA-T4 1µl 
APC Cy7 conjugated 
anti-human CD14 






3.1 Isolation of Peptide Specific CD4+ T-cells from Healthy EBV Seropositive 
Donors 
In order to isolate PRS specific CD4+ T-cell clones, we used a peptide:MHC class II 
tetramer (pMHC) loaded with the EBV PRS peptide, derived from the latency III 
protein EBNA2 and presented through HLADR7 (DR7/PRS). Fluorescent activated cell 
sorting (FACS) and limiting dilution cloning was performed on PBMCs, ex vivo. To 
generate CD4 T cell clones representative of cells within the peripheral circulation 
without in vitro expansion, PBMCs were isolated from the peripheral blood of 2 healthy 
EBV seropositive, HLADR7+ donors. CD4+T cells were negatively isolated from these. 
The CD4+ T cells were then exposed to the PE-conjugated pMHC tetramer complex 
(DR7/PRS) and surface stained with APC conjugated anti-CD3 and ECD conjugated 
anti-CD4 antibodies. The gating strategy for FACS is shown in Figure 3.1A. We gated 
on singlets, followed by lymphocytes and CD3+ CD4+ T cells. The DR7/PRS tetramer 
positive CD4+ T cells within this gate were collected. 
The results, as indicated in Figure 3.1B and 3.1C, show the frequencies of DR7/PRS 
tetramer positive CD4+ T cell populations present within the peripheral blood of each 
healthy donor. The percentage frequencies were 0.1% of donor 1 and 0.025% of donor 
2’s total CD4+ T cell populations. 
In order to isolate CD4 T cell clones originating from single epitope specific 
populations, FACS sorted cells were plated out by limiting dilution cloning at 0.3, 3 and 




autologous LCLs and 1 million PHA-treated allogeneic buffy coat feeder cells per well 
(both previously irradiated with 4000 rads). The aim was to generate monoclonal 













































EBV positive Donor 1  
CD4 
(B) (C) 
Singlets Lymphocytes CD3+ CD4+ T 
cells 
0.1% 0.025% 
Figure 3.1 Fluorescent activated cell sorting of DR7/PRS positive CD4+ T cell 
populations  
Analysis of CD4+ T cells populations from 2 EBV seropositive healthy donors stained 
with DR7/PRS tetramer conjugated to PE, followed by anti-CD3 and anti-CD4 
antibodies. (A) CD4+ T cell gating strategy. From left to right: singlets, lymphocytes, and 
CD3+ CD4+ T cells. (B) Donor 1 sorted CD4+ T cells. The sorting gate shows 0.1% of 
the total CD4+ T cell population. (C) Donor 2 sorted CD4+ T cells. The sorting gate 




3.2 Characterisation of T Cell Clones. 
3.2.1 IFNγ Production in Response to Target PRS Peptide 
From each healthy donor, the growing CD4+ T cell clones were screened for their 
specificity against the PRS peptide epitope. After a period of 2 weeks of T cell 
expansion, 155 growing clones from donor 1 were screened. To increase the probability 
that the proliferating cells originated from single cells, we concentrated on the growing 
clones from the 0.3c/w and 3c/w micro-culture plates. T cells were co-cultured with 
50,000 HLADR7+ autologous LCL targets (per well) either un-manipulated or pre-
loaded with 5µg/ml of PRS peptide epitope. T cell clones were also co-cultured with 
media alone or containing 5µg/ml of PRS peptide epitope. Positive CD4 T cell clones 
were identified by an increased response to LCL target pre-loaded with PRS peptide 
epitope over un-manipulated LCL and standard media combined with peptide epitope 
over media alone. 
As illustrated in Figure 3.2, for the first 50 clones of the 155 T cell populations screened 
for donor 1, only a small proportion showed a greater response towards the LCL pre-
loaded with PRS epitope than without peptide and to media with peptide above media 
alone. This represented 25% of the total 155 screened clones (Table 3.1). This was a 
relatively low yield obtained, most likely as a result of the gating strategy used in the 
FACs cell sorting for this donor (Figure 3.1), which incorporated a higher proportion of 
none specific CD4+ T cells. 
After 2 weeks of T cell expansion 192 growing clones derived from donor 2 were 
similarly selected from the 0.3c/w and 3c/w micro-culture plates and screened for their 




displayed in Figure 3.3, which shows the first 50 clones screened. As illustrated out of 
the 192 clones screened 186 showed a response towards PRS which represented a yield 
of 97% (Table 3.1). This increased yield reflects the tighter gating applied during the 
FACS sorting (Figure 3.1). 
PRS specific clonal populations from each donor were re-stimulated with HLADR7 
matched LCL and Feeder cells and expanded further in vitro. The unresponsive non-
specific clones were discarded. A summary of the FACS sorting, limiting dilution 
cloning and specificity screening is shown in Table 3.1. As indicated in the table, 31 
PRS specific clones from donor 1 and 28 PRS specific clones from donor 2 were then 































Figure 3.2 IFNγ ELISA screening of T cell clones from Donor 1  
T cells from proliferating micro-cultures were co-cultured with autologous LCLs and 
LCLs pre-exposed to PRS epitope peptide. T cells were also co-cultured with standard 
media alone and standard media containing epitope peptide. Analysis of supernatant 
was conducted via IFNγ ELISA method. The first 50 clones of the 155 screened are 







































Figure 3.3 IFNγ ELISA screening of T cell clones from Donor 2 
T cells from proliferating micro-cultures were co-cultured with autologous LCLs 
and LCLs pre-exposed to PRS epitope peptide. T cells were also co-cultured with 
standard media alone and standard media containing epitope peptide. Analysis of 
supernatant was conducted via IFNγ ELISA method. The first 50 clones of the 192 






































  Donor 1 Donor 2 
PBMCs extracted  20 million 50 million 
Isolated CD4+ T cells 6 million 40 million 
FACS sorted DR7/PRS 
positive CD4+ T cells 
8000 (0.1%) 10,000 (0.025%) 
Growing Clones screened 
for PRS specificity 
155 192 
Number & percentage of 
PRS specific clones 
39 (25%) 186 (97%) 
Number of PRS specific 
clones taken forward for 











Table 3.1 Summary of peptide specific CD4 T cell clones isolated from whole 
blood, ex vivo 
This summarises the number of original PBMCs extracted from each HLADR7+ 
matched donor, the number of isolated CD4 T cells, FACs sorted populations, 
growing clones assessed for PRS specificity, number and percentage of PRS specific 




3.3 Determination of T Cell Clonal Vβ usage 
3.3.1 TCRVβ Repertoire Staining  
After confirming the clones retained their PRS specificity following expansion, we then 
went on to examine their TCRVβ usage. These experiments used the multi-parametric 
IOTest Beta Mark TCR Repertoire Kit (Beckman Coulter) in flow cytometry, which 
contains a panel of 24 monoclonal antibodies specific for different TCRVβ families. 
The kit provides approximately 70% coverage of the human TCRVβ repertoire, and the 
Abs (antibodies) are provided in mixes. This allows for the detection of 3 different 
TCRVβs within the same tube. To limit the analysis required, a matrix was constructed 
enabling analyses of multiple clones together. The matrix for donor 1 is displayed in 
Figure 3.4, and was constructed such that each clone was present in a unique 
combination of 2 pools. Pools of clones were stained using the repertoire kit. This meant 
that each T cell clone was stained twice with the antibody mixes, in two different pools 
of clones. 
As illustrated by Figure 3.5, pools of clones were gated on live CD3+ T lymphocytes. 
This gating strategy was used throughout all repertoire staining. As a control, an aliquot 
of each pool of clones was viability and surface stained with a CD3 surface antibody, 
but not stained with the IOTest Beta Mark Kit antibody mixes. There was no positive 
staining in the absence of these TCRVβ antibody mixes (Figure 3.5B). 
Figure 3.6 shows density plots for two pools of clones from donor 1; iv and x stained 
with the panel of TCR Vβ antibodies. As indicated by the density plots (A-H), each pool 
of clones was divided out among 8 separate tubes and stained with relevant TCRVβ 




(14.46%) and of Vβ1 was seen within tube F (29.21%) (Figure 3.6A). Within pool x 
positive expression for Vβ5.1 (1.89%) in tube C and Vβ1 within tube F (46.89%) are 
also shown (Figure 3.6B). Interestingly, these two pools both revealed Vβ1 usage 
indicating that one of the clones in each of these pools expressed a TCR with Vβ1 
usage. Similar analysis was performed for all pools of clones; i-xi. 
Figures 3.7 summarises the findings gained from TCRVβ repertoire staining of pools of 
clones from donor 1. To decipher which of the clones within the pools were expressing 
the TCRVβ detected, we cross matched any percentage expression of Vβ usage, within 
the matrix. For example, after cross matching the Vβ1 expression detected in pools iv 
and x, this was indicative of clone 99. Similar cross-matching of all the results in the 
pools i-x, allowed for the determination of specific clones to be taken forward for 
















i ii iii iv v vi 
vii 2 4 18 19 21 26 
viii 28 33 41 49 53 57 
ix 64 74 78 79 83 91 
x 94 96 97 99 101 110 











Figure 3.4 Matrix strategy for analysis of TCRVβ usage 
 A matrix was constructed to enable analysis of PRS specific CD4+ T cell clones in 
pools. Each individual T cell clone is present in 2 unique pools. Example of donor 1 








































Figure 3.5 TCRVβ repertoire analysis gating strategy 
(A) TCRVβ repertoire analysis gating strategy. From left to right: singlets and alive CD3+ 
























Figure 3.6 Donor 1 TCRVβ repertoire analysis 
TCRVβ repertoire staining of clonal pools iv and x from donor 1. Pools of clones were made, 
divided among 8 tubes (A-H) and stained with relevant Vβ repertoire antibody mixes. Results 
are gated on live CD3 lymphocytes and any positive Vβ staining is presented as an increase 
in percentage of single/double staining. (A) Pool iv contained positive staining in tube E, 
indicating Vβ12 usage (14.46%) and tube F indicating Vβ1 usage (29.21%). (B) Pool x 
contained positive staining in tube C indicating Vβ5.1 usage (1.89%) and in tube F indicating 
Vβ1 usage (46.89%). 
Tube A Tube B Tube C Tube D 
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(A)  Pool iv 







i ii iii iv v vi Positive 
Vβ usage  
% 
vii 2 4 18 19 21 26 Vβ5.1 (5%) 
Vβ21.3 (12%) 
Vβ23 (11%) 
viii 28 33 41 49 53 57 Vβ1 (20%)  
Vβ22 (7%) 
ix 64 74 78 79 83 91 Vβ1 (25%) 
Vβ2 (11%) 
x 94 96 97 99 101 110 Vβ1 (47%) 
Vβ5.1 (3%) 
Xi 122 127 131 149 153 154 Vβ1 (18%) 
Vβ12 (16%) 
Positive 
Vβ usage  
% 

















Figure 3.7 Donor 1 TCRVβ repertoire analysis summary 
Summary of TCRVβ repertoire staining on donor 1 clones. Any positive Vβ usage found 




3.3.2 TCRVβ Individual Staining 
To confirm the Vβ usage of individual T cell clones, staining was performed using 
antibodies against individual TCRVβ. Live CD3+ CD4+ T lymphocytes were gated on 
(Figure 3.8A). This gating strategy was used throughout all individual Vβ staining. As a 
control, cells were viability and surface stained with anti CD3 and anti CD4 surface 
antibodies but not stained with Vβ antibodies. There was no positive staining in the 
absence of these individual Vβ antibodies (Figure 3.8b). Figure 3.8 displays the 
individual TCRVβ staining performed on clone 99, as previously indicated by the 
matrix strategy to express Vβ1 (Figure 3.7). The results show a shift in the staining in 
the presence of Vβ1 Abs, with 94.47% positive expression for Vβ1 usage, indicating 
that clone 99 used Vβ1. 
Similar experiments were repeated on all clones where positive staining was seen in the 
matrix (Figure 3.7). Figure 3.9 provides a summary of the positive results obtained for 
donor 1. Using this strategy, we successfully found the Vβ usages of 7 clones. Among 
these, 4 clones (clone 53, clone 83, clone 99 and clone 110) were positive for Vβ1 
usage, 2 clones (clone 2 and clone 21) were positive for Vβ21.3 usage and clone 91 was 
positive for Vβ2 usage. In each case over 90% of the T cell population was positive for 
the relevant Vβ.   
Similar analysis was performed on the T cell clones isolated from donor 2. Figure 3.10 
summarises the findings from TCRVβ repertoire analysis utilising a similar matrix 
strategy as used for on donor 1. Again, Abs staining was used to confirm the results 




could be confirmed. Among these, 2 clones (clone 2 and clone 49) were positive for 
Vβ2 usage, 2 clones (clone 14 and clone 15) were positive for Vβ5.1 usage and clone 
46 was positive for Vβ17. Again, all of which showed a shift in staining above 90%.  
Table 3.2 summarising the findings gained from this individual TCRVβ staining for 
both healthy donors.   
Interestingly, from these results T cells specific for the same peptide epitope-MHCII 
combination but with different Vβ usages were isolated from each donor. Both donors 
had T cells utilising Vβ2 (Donor 1 clone 91) (Donor 2 clones 2 and 49) and within 
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Figure 3.8 Individual TCRVβ usage analysis 
 (A) Individual TCRVβ analysis gating strategy. From left to right: singlets, alive 
lymphocytes and CD3+ CD4+ T cells (B) Controls; no Vβ. This gating strategy was used 
throughout all individual staining. (C) Clone 99; positively stained with anti-Vβ1 























Figure 3.9 Donor 1 summary of individual TCRVβ staining 
Histograms represent individual T cell clones (200,000 cells) stained with viability dye, 
anti-CD3 APC, anti-CD4 ECD and 7µl of individual TCRVβ monoclonal antibodies, 
conjugated to either PE or FITC. Percentages within each histogram represent frequencies 
of PRS specific CD4+ T cells in each clonal population stained positively for a specific Vβ. 
99.64% 
Clone 21 Vβ21.3  
99.39% 
Clone 2 Vβ21.3  
Clone 53 Vβ1 
99.84% 
Clone 83 Vβ1 
99.96% 
Clone 91 Vβ2  
90.33% 
Clone 99 Vβ1  
94.47% 
99.99% 









Clonal Pools  i ii iii iv v Positive 
Vβ usage  
% 
vi 1 2 
  3 5 7  Vβ5.1 (9%) 
Vβ2 (27%) 
vii 10 
  11 12 14 15  Vβ5.1 (43%) 
viii 17 27 28 30 35  
ix  38 39 40 41 42  Vβ8 (7%) 
 Vβ2 (28%) 
x 43 44 45 46 47  Vβ17 (26%) 
 Vβ5.1 (3%) 
 Vβ2 (11%) 
Xi  48 49        Vβ2 (44%) 
Positive 



















Figure 3.10 Donor 2 TCRVβ repertoire analysis 
Summary of donor 2 TCRVβ repertoire staining. Any positive expression for a particular 

























Clone 15 Vβ5.1  
99.62% 






Clone 46 Vβ17  
95.57% 
Clone 49 Vβ2  
90.56% 
Clone 14 Vβ5.1  
FITC 
Figure 3.11 Donor 2 individual TCRVβ usage analysis 
Histograms represent individual T cell clones (200,000 cells) stained with viability dye, 
anti-CD3 APC, anti-CD4 ECD and 7µl of individual TCRVβ monoclonal antibodies, 
conjugated to either PE or FITC. Percentages within each histogram represent frequencies 





Donor 1 Vβ Usage 
Vβ Positive Clones 
Vβ1 C53, C83, C99 & C110 
Vβ2 C91 
Vβ21.3 C2 &C21 
Donor 2 Vβ Usage 
Vβ Positive Clones 
Vβ2 C2 & C49 











Table 3.2 Summary of TCRVβ usage analysis. 




3.4 Determination of T-cell Functional Avidities 
Having isolated individual PRS specific T cell clones with different Vβ usages, we were 
now interested in whether TCR usage affects T cell function. We therefore measured the 
functional avidity of each clone with known Vβ usage in peptide titration assays. In 
these assays, the T cells were exposed to a series of peptide dilutions ranging from 
1x10-5 to 1x10-10 M, in the presence of autologous LCL as antigen presenting cells. As 
indicated by Figure 3.12, within these experiments, functional avidity was defined as 
the peptide concentration required to produce 50% of the maximum IFNγ release. The 
final functional avidities were converted from M to nM concentration. Figure 3.12 
demonstrates that the PRS specific clones from both healthy donors displayed a range of 
differing functional avidities. In donor 1 these ranged from 0.25nM to 30nM, whereas 
in donor 2 these were consistently much lower and ranged from 20nM to 40nM.  
Importantly, these experiments also showed that certain clones produced a IFNγ 
response towards autologous LCL in the absence of exogenously supplied PRS peptide 
as a response was seen at 0M. This suggested that these T cell clones could recognise 
naturally processed peptide epitope on the EBV infected LCL targets. This response 
appeared to differ between the two individuals, with all clones from donor 1 able to 
recognise the un-manipulated autologous LCL cells, whereas only 2 clones from donor 
2 (clones 2 and 49) were similarly able to produce a response. These results gave the 
first indication that certain clones within each healthy donor might function more 
effectively than others, as demonstrated by the higher levels of IFNγ release, seen in 





































Figure 3.12 Functional avidities of PRS specific clones 
CD4+ T cell Clones of known Vβ usage (2000 cells per well) were stimulated overnight with 





 M concentrations. Controls used included T cells co-cultured with culture media alone 
and HLADR7+ autologous LCL co-cultured with media alone. All conditions were performed 
in triplicates. Responses were assayed by IFNγ release in picograms per millilitre. Functional 
avidities were determined as the peptide concentration required to produce 50% maximal 
response (A) Donor 1 clonal functional avidities ranging from 0.25 to 30nM (B) Donor 2 

































































3.5 T Cell Clonal Recognition of Naturally Processed and Presented PRS Peptide 
Epitope 
The ability of a T cell to respond to peptide exposed LCL targets in vitro is important, 
as it indicates the specificity of a T cell and its functional avidity. However, for antigen 
specific T cells to have therapeutic relevance in vivo, as direct effectors, the T cell must 
also be able to recognise antigens presented by naturally infected B lymphocytes. 
Recognition of un-manipulated autologous LCL replicates how the CD4 T cells within 
the peripheral blood, may respond to virus infected cells, in vivo. Success of this would 
imply that such T cells may have direct effector functioning in the immune control of 
EBV infection and B cell lymphomas. Therefore, we further explored the capability of 
the PRS specific T cell clones to recognise autologous un-manipulated LCL target. 
The LCL recognition efficiency of each T cell clone was examined through co-culturing 
T cells with HLADR7 matched or mismatched LCL targets, with no prior exogenous 
PRS peptide treatment, compared to the same LCL targets pre-exposed to PRS peptide 
epitope. The efficiency with which each clone recognised the un-manipulated 
autologous LCL target, as displayed in Figure 3.13, was expressed as a percentage of 
the maximal response seen against the same HLADR7 matched LCL target pre-loaded 
with optimal PRS peptide. 
Figures 3.13 shows representative LCL recognition efficiencies for the clones derived 
from each healthy donor. To obtain accurate results and prevent anomalies, three 
replicate LCL recognition assays were performed and a mean was formulated from 
these. As expected, donor 1 derived clones showed strong recognition of matched LCL 




when pre-exposed to peptide. All clones from donor 1 also recognised the un-
manipulated autologous LCL at differing percentages ranging from 13% to 29%. In 
particular, clone 21, clone 53 and clone 99 all produced concentrations of IFNγ at high 
percentage efficiencies compared to peptide loaded LCL (clone 21; 29%, clone 53; 
24%, and clone 99; 29%), and in previous assays displayed similarities in functional 
avidity (Figure 3.13). Interestingly, clones 53 and 99, both showing high percentage 
LCL recognition efficiency, both expressed TCRs using Vβ1. However, two other 
clones with this same Vβ usage (clone 83 and clone 110) had lower efficiency of LCL 
recognition (Summarised in Table 3.3).  
Similar experiments were performed on the clones from donor 2. Figure 3.13 illustrates 
that these clones showed an overall weaker recognition of the matched LCL target pre-
loaded with PRS peptide epitope, compared to donor 1 clones, indicated by the lower 
IFNγ release. Again, there was no recognition of the control un-manipulated 
mismatched LCL. In donor 2, 4 out of the 5 clones analysed recognised the un-
manipulated autologous LCL target cells at percentage efficiencies ranging from 5%-
12%, however clone 46 was unable to do this. Interestingly, the percentage recognition 
efficiencies of donor 2 were all lower than the clones isolated from donor 1, matching 
with their lower functional avidities, as shown in Figure 3.13, in the peptide titration 
assays and thus their inability to see LCL targets. 
Table 3.3 and table 3.4 summarise the findings from both Vβ usage and functional 
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Figure 3.13 T-cell efficiencies.  
T cell clones (100 to 5000 T cells per well) were co-cultured with HLADR7 matched 
LCL or mismatched LCL (5x104 cells per well), both previously exposed to PRS peptide 
epitope and compared to the same LCLs targets with no prior exogenous peptide 
treatment. Responses are shown as IFNγ release in picograms per millilitre. Boxes show 
percentage efficiency of responding cells. Percentage efficiency is the mean of replicate 





TABLE 3.3  
Donor 1 HLA/DR7 restricted EBNA2/PRS clones  
Clones Vβ Usage Functional avidity 
(concn (nM)) 
% Recognition of 
LCL  
Clone 2 Vβ21.3 5  15 
Clone 21 Vβ21.3  0.25 29 
Clone 53 Vβ1  5 27 
Clone 83 Vβ1  30 18 
Clone 99 Vβ1 5 29 
Clone 110 Vβ1  10 21 
Clone 91 Vβ2  9 13 
 
TABLE 3.4 
Donor 2 HLA/DR7 restricted EBNA2/PRS clones  
Clones Vβ Usage Functional avidity  
(concn (nM) ) 
% Recognition of 
LCL  
Clone 2 Vβ2 20   8 
Clone 49 Vβ2 30  12 
Clone 14 Vβ5.1 30   5 
Clone 15 Vβ5.1 40  7 








 Tables 3.3 & 3.4 Summary of EBNA2 PRS specific CD4+ T cell clones’ Vβ usage 
and functionality.   
Functional avidity is defined as the concentration of epitope peptide mediating 50% of 
the maximal IFNγ produced in peptide titration assays. Values shown are the means of 
the results of single assays for each clone using triplet replicates of each peptide 
concentration. Recognition of the un-manipulated autologous LCL, is expressed as a 
percentage of the IFNγ production seen in the same assay against the same matched 
LCL target but optimally loaded with PRS peptide epitope.  The percentage values for 




3.6 TCR Profiling 
To further investigate the relationship between TCRVβ usage and T cell function, alpha 
and beta chains of TCRs from clones were sequenced to determine if there were 
similarities in nucleotide sequences within the beta variable domain CDR3 region.  
Donor 1 clones using Vβ1 and Vβ21.3 were selected for this TCRseq. These showed 
interesting results in relation to TCRVβ usage and function in terms of functional 
avidities and percentage LCL recognition efficiency. 
In order to isolate the alpha and beta genes from these clones, an RNAeasy plus 
microkit and a SMART RACE cDNA amplification kit were used. Cellular RNA was 
extracted using the RNAeasy plus microkit and converted via reverse transcription into 
cDNA. Both the alpha and beta TCR DNA was then amplified using rapid amplification 
of cDNA ends (RACE) PCR with primers specific for each alpha and beta chains, along 
with negative controls.  
As shown in Figure 3.14 gel electrophoresis was performed and from each clone we 
successfully amplified PCR products with the correct size from both alpha and beta 
chains of the T cell receptors (200bps in length). Alpha and beta chain DNA from each 
clone was then extracted and purified using a gel extraction spin column method and 
prepared for sequencing. Unfortunately, from the sequencing data obtained we were 
unsuccessful in generating any conclusive data, therefore further troubleshooting is 






























Figure 3.14 Gel electrophoresis of clonal TCR alpha and beta chain cDNA 
Alpha and beta TCRs from the CD4+ T cell clones were amplified using alpha and beta gene 
specific primers and a universal primer mix, via RACE PCR. The size of RACE DNA 
products was confirmed on a 1% agarose gel, via gel electrophoresis. For all CD4+ T cell 
clones each α and β primer yielded a PCR product of expected size (200bp). Controls 
containing no DNA (-) did not produce any PCR product. (A) From left to right; positive DNA 
products of clone 2 alpha and beta chains (C2α+) (C2β+), clone 2 alpha and beta chain 
negative controls (C2α-) (C2β-) and positive DNA products of clone 21 alpha and beta chains 
(C21α+) (C21β+). (B) From left to right; clone 21 alpha and beta chains negative controls 
(C21α-) (C21β-), positive DNA products of clone 53 alpha and beta chains (C53α+) (C53β+), 
and clone 53 alpha and beta chain negative controls (C53α-) (C53β-). (C) From left to right; 
positive DNA products of clone 83 alpha and beta chains (C83α+) (C83β+), clone 83 alpha 
and beta chain negative controls (C83α-) (C83β-), and positive DNA products of clone 99 
alpha and beta chains (C99α+) (C99β+). (D) From left to right; clone 99 alpha and beta chains 
negative controls (C99α-) (C99β-), positive DNA products of clone 110 alpha and beta chains 




















The αβTCR is essential for determining the antigen specificity of T lymphocytes of the 
adaptive immune system. Previous research into T cell-based therapies for viral diseases 
and cancers includes the development of novel methods, such as TCR gene transfer 
therapy, in which antigen specific TCRs, are genetically introduced into cytotoxic or 
helper T lymphocytic populations. However, currently TCR selection from the broad 
αβTCR repertoire remains a significant challenge. Epitope specific populations within 
this repertoire are known to be extremely diverse and contain a substantial proportion of 
cells expressing low affinity and avidity TCRs.  
Analysis of cytotoxic T cell responses towards single peptide epitopes, in HLA matched 
humans has revealed identical TCR sequence usage, in the context of various viral 
models (Crompton et al 2008, InYoung Song et al 2017).  However, the biological 
mechanisms by which clonal restriction occurs and how this distinct TCR usage 
influences effector mechanisms remain unclear. Further, assessment of which TCR Vβs 
and TRBV gene segments, induce the most effective antigen-specific immune 
responses, based on T cell function, is vital for optimisation of future gene transfer 
immunotherapies for various cancers.   
We sought to investigate these concepts, through analysis of the less well studied CD4+ 
T cell immune response, in the context of the globally prevalent gamma-herpes virus, 
Epstein Barr Virus. In spite of the robust innate and adaptive immune responses 
controlling the virus in the majority of people infected, EBV has been associated with 




the MHC class II molecule. This is essential for subsequent processing and presentation 
of EBV exogenous proteins, enabling successful CD4+ TCR recognition and 
subsequent anti-viral immune control. Despite previous belief that direct effector 
functioning was entirely related to CD8+ T cells, it has now been established that 
certain subtypes of CD4+ T cells can also directly target antigen-positive cells through 
MHCII. These helper type cells have been reported to express various phenotypic 
markers of known cytotoxicity including perforin and granzyme A linked to CD8+ 
functioning (Appay et al 2002) and thus are of significance importance during viral and 
cancer cell elimination. Unfortunately, within patients suffering from B cell 
malignancies such as post-transplant lymphoproliferative disease (PTLD), peripheral 
EBV specific CD4+ T cell populations are of low frequency due to immunosuppression. 
However, they have now been observed in healthy seropositive individuals to respond 
to a large array of EBV derived antigens, with cytotoxic effects (Long et al 2005, Long 
et al 2011).  
This project focussed on the EBV latency III protein, EBNA2 restricted through 
HLADR7. Many of the proteins’ epitopes have now been identified and have been 
further shown to be presented well by MHCII on infected B lymphocytes (Long et al 
2005). EBNA2 is expressed in latency III positive tumours, such as PTLD, therefore it 
is thought to have the potential to be an important immunotherapeutic target for the 
long-term treatment of this lymphoproliferative disease.   
Based on these considerations we aimed to investigate the relationship between TCR 
repertoire usage and effector functioning of epitope specific CD4+ T cells in healthy 
EBV carriers, utilising the EBNA2-derived PRS epitope as a model. Previous work in 




populations specific for PRS, contain T cells with multiple different Vβ usages. 
However, further analysis of TCR sequence homology is yet to be performed. We 
hypothesised that the TCR usage may affect T cell function, with some TCRs therefore 
being of greater therapeutic benefit than others.  
 
4.1 Generation and Screening of PRS specific CD4+ T cell clones 
To address this hypothesis, we successfully isolated PRS specific CD4+ T cells from 
two healthy HLA DR7+ seropositive donors using MHC class II tetramer staining and 
FACS sorting, directly ex vivo. Previous generation of clonal populations, has focussed 
on isolation from peripheral blood mononuclear cells (PBMCs) with a period of antigen 
stimulation and culturing leading to higher enrichment but lower purity levels.  
The ex vivo generation implemented within this study was important to maintain the 
TCR repertoire diversity of the sorted CD4+ T cells to reflect that present in vivo. Prior 
in vitro stimulation may lead to skewing of the TCR repertoire as some subclonal 
populations may expand more than others affecting the phenotype and functioning, thus 
having negative implications on subsequent TCR usage analysis.  
The percentage frequencies of DR7/PRS tetramer positive CD4+ T cells detected in 
each healthy donor was low, 0.1% in donor 1 and only 0.025% in donor 2. This would 
imply that within the total EBV specific CD4+ T cell immune responses of HLADR7 
positive healthy carriers, PRS specific responses constitute a very low proportion. 
However, similar low frequencies of MHC class II tetramer positive CD4+ T cell 




in vitro work on healthy long term EBV carriers (Long et al 2013). Generally, within 
EBV specific immune responses, the magnitude of CD4+ T cells within the peripheral 
blood is much lower compared to the immunodominant CD8+ populations  (Long et al 
2011).   
To obtain clonal populations, the T cells were FACS sorted and subjected to limiting 
dilution cloning. The growing clones were then screened for their specificity against the 
PRS epitope. The functional readout for peptide epitope specificity screening and 
upcoming assays was determined by IFNγ production. CD4+ T cells producing this 
particular cytokine have been observed to display both anti-viral and anti-tumour 
therapeutic effects, being Th1 in subtype (Swain et al 2012). Within each healthy donor, 
not all the growing clones made IFNγ in response to the PRS peptide epitope. Analysis 
of T cell responses during both chronic viral infection and cancer, has revealed that 
repeated cellular stimulations and expansions can render some specific T cells 
exhausted meaning proliferative capacity and cytokine production can consequentially 
be reduced (Wherry et al 2011). These fatigued memory effector cells have limited 
persistence, reducing their response rates and therapeutic effectiveness. This may have 
occurred within our limiting dilution cultures, which were cultured for 2-3 weeks prior 
to peptide specificity screening.  
However, more likely, the non-responsive wells contained non-specific T cells. We 
found differences in percentage yield of PRS-specific clones generated from donor 1, 
25%, compared to donor 2, 97%. These differences can be explained by the gating 
strategy used during FACS sorting of the DR7/PRS tetramer stained populations. The 




lower percentage would be specific for the PRS epitope. This gating was corrected for 
donor 2.  
A further factor to consider is the potential outgrowth of polyclonal T cell populations 
due to more than one cell being plated into each well of the limiting dilution cloning. 
Although the clones were preferentially selected from the 0.3c/w plates reducing the 
probability of selecting polyclonal populations, some clones within these populations 
may have contained two or more T cells, with non-specific TCRs, outgrowing the PRS 
specific cells.  
Another potential reason for a lack of IFNγ production in some of the clones screened 
could have been the result of other subsets of PRS specific CD4+ T cells being present 
within the cultures screened, producing other types of cytokines not assayed for, such as 
IL-4 linked to the helper subtype; Th2. sRNA sequencing and cyTOF mass 
spectrometry has revealed that T cells within the same monoclonal population 
containing the same TCR, have the capacity to downregulate certain transcription 
factors for one differential status, and upregulate a different one to produce a new subset 
of cells (Hans et al 2014).  Within this study, MHC class II tetramer staining performed 
prior to dilution cloning and screening selected T cells based on specificity of their 
TCR, thus this had no influences on the activated cells subset lineage and effector 
function. 
There was the additional possibility of polyfunctional T cells growing within the 
cultures screened, producing multiple different cytokines not assayed for. Previous 
work conducted by Betts et al demonstrated this phenomenon in the context of HIV 




responses there was little or no production of IFNγ but in fact many other cytokines 
were secreted instead, highlighting the functional heterogeneity of anti-viral T cell 
immune responses (Betts et al 2006). Within our own laboratory it has been further 
shown in the context of EBV specific CD4+ T cells in healthy carriers, these cells can 
produce high levels of the cytokine TNFα along with IFNγ, and sometimes in its 
absence. (Benjamin Meckiff, unpublished data). In the context of CMV specific CD8+ 
T cell immune responses, work conducted by Sanberg and colleagues also reported 
within polyfunctional T cell populations, the type of cytokine being secreted determined 
functional differentiation of a T cell, with TNFα production representing an earlier stage 
of cellular development compared to IFNγ and IL-2 (Sanberg et al 2001).  Therefore, 
the use of ELISplots would be a beneficial form of future analysis to determine whether 
any of the unresponsive T cell populations within our growing cultures were in fact 
other subsets producing different cytokines, polyfunctional populations or at a differing 
stage of functional development. 
Interestingly, we noticed that some clones did additionally appear to produce IFNγ in 
response to the unmanipulated LCL target in these screening assays, which suggested 
they might have the ability to recognise naturally processed and presented exogenous 
cognate antigen epitope, from the resident EBV genome. This is extremely important 
from a clinical standpoint, as the ability to recognise naturally infected B cell targets 
would imply that such T cells may have direct effector functions in the long-term 






4.2 TCRVβ usage analysis of PRS specific CD4+ T cell clones 
We next explored the TCRVβ repertoire usage of the PRS-specific T cell clones, in 
order to assess the range of TCRs specific for the PRS epitope. This additionally 
enabled us to confirm the clonality of the T cells as all cells within a clonotypic 
population should express the same V/D/J segment and identical TCRVβ protein.  
Interestingly, we were only able to determine the Vβ usage of a small subset of the 
clones screened.   This conservation of TCR usage may have been due to the limitation 
of the IOTest Beta Mark Kit utilised, in which the monoclonal antibody panel, 
identifying 24 separate TCRVβ families, only covers up to 70% of the normal human 
αβTCR repertoire. Therefore, less common TCRVβs being used by clones not covered 
for by the kit, may have been consequentially missed. Previous assessment of TCRVβ 
repertoire diversity using the IOTest Beta Mark Repertoire kit, has similarly identified 
significant proportions of T cells within a population failing to react to any TCRVβ 
antibody tested (Tembhare et al 2011).  
Nevertheless, we successfully identified the Vβ usage of a number of clones from each 
healthy donor. From donor 1 out of the 31 clones assessed, 7 showed Vβ usage for 
Vβ21.3, Vβ1 or Vβ2; 22.5%. In comparison, within donor 2 only 5 clones from the 28 
clones analysed showed Vβ usage for Vβ2, Vβ5.3, or Vβ17; 17.9%. Most interestingly, 
similarities in Vβ2 usage between the donors was apparent. The distinct Vβ usage 
observed in both donors is indication that a particular mechanism is favouring their 
occurrence.  
During epitope specific CD8+ T cell immune responses against chronic EBV infection, 




including, Vβ2, Vβ4, and Vβ16. (Lim et al 2000).  In the context of other chronic viral 
infections, previous sequence analyses have similarly observed immunodominance of 
individual TCR gene segments associated with a defined sets of CDR3 motif sequences 
in both epitope-specific CD8+ T cell and CD4+ T cell populations, despite broad TCR 
repertoires available (Chrompton et al 2008, InYoung Song et al 2017). These findings 
highlight the importance of structural immunodominance within differing TCRs 
responding to the same MHC-peptide combination. In the context of CD4+ T cells, 
TCR repertoire analysis has demonstrated that restriction to particular subsets of Vβ 
subfamilies such as Vβ2 and Vβ17 does occur within populations of antigen 
experienced CTLs (Appay et al 2002).  Similarly, within our own laboratory 
investigations into the diversity of the TCR repertoire usage of CD4+ T cells in healthy 
EBV carriers has shown overrepresentation of single Vβ chains (Benjamin Meckiff, 
unpublished data).  
The biological basis for this TCRVβ repertoire focussing and clonal selection observed, 
remains subject to further in-depth characterisation and investigation. EBV is 
reactivated throughout the lifetime of an infected individual, thus it is likely that PRS 
specific CD4+ T cells have been chronically exposed to this particular latent antigen 
epitope, resulting in the continuous activation of specific clones with conserved TCR 
structural components. Subsequently this would result in antigen driven selection of a 
distinct subset of immunodominant TCRs arising within seropositive healthy 
individuals.  
It has been further speculated that the processing and presentation pathways  antigen 
presenting cells along with HLA allele restriction of epitope specific CD4+ T cell clonal 




usage (Chrompton et al 2008). However further investigations are required to assess 
these possibilities. 
From our own results and others, this therefore suggests that, despite the initial diverse 
TCRVβ repertoire availability within CD4+ T cell immune responses, clonal selection 
along with immunodominance of individual TCR structural components does occur 
within epitope specific populations. Homogenous TCR responses to immunodominant 
epitopes such as PRS may be important for activation of T cells conferring the most 
robust immune responses. However, further analysis is required in order to determine 
the exact factors having greatest influence on this TCR immunodominance. 
 
4.3 Functional analysis of PRS specific CD4+ T cell clones with known Vβ usage   
Having established PRS specific CD4+ T cell clones and confirmed their Vβ usages, we 
were next interested in gaining a better understanding of their functional characteristics. 
The initial parameter investigated was functional avidity; the biological measure of the 
ex vivo response produced by a T cell to a given concentration of target peptide. The 
potency of cellular immune responses strongly depends on this functional characteristic. 
Within the context of various viruses, epitope specific T cells displaying high functional 
avidity have been associated with better viral clearance.  Analysis was achieved through 
measuring the IFNγ production in response to stimulation with an autologous LCL 
target pre-loaded with titrating amounts of PRS peptide.  
The clones displayed various avidities ranging from 0.25 to 40nM. Interestingly, the 
functional avidities of the clones isolated from donor 1 were generally higher than those 




T cell clones against the same epitope-HLA allele combination appeared functionally 
alike to one another, with regards to peptide titration curves. However, these previous 
experiments investigated this functional characteristic on only a small number of clones 
for each epitope, and similarly to other studies, these cells were subject to repeated prior 
in vitro stimulations and expansion before cloning. This would have increased the 
likelihood of preferential expansion of certain clones inducing bias to the avidity 
measurements produced. Despite this, in the context of PRS-specific CD4+ T cell 
clones, restricted through different HLA alleles functional avidities were reported to 
range from 3-30nM (Long et al 2005). Similarly, peptide titration analysis has reported 
avidities of CMV epitope specific CD4+ T cell clones ranging from 10nM-100nM, in 
line with CD8+ cytotoxic cellular responses (Chrompton et al 2008).  In the context of 
other viruses such as HIV, work conducted by Billeskov et al found that low antigen 
dosage in adjuvant-based vaccination selectively induced CD4+ T helper cells with 
enhanced functional avidity, increasing cytokine production, along with improving the 
efficacy of CD8 T cell anti-viral activity (Billeskov et al 2017). This coincides with the 
results generated from these peptide titration assays, that certain clones with high 
functional avidity could respond with higher levels of IFNγ cytokine release to low 
levels of peptide. These results, therefore, infer that certain clones may be associated 
with more potent responses against infections and cancers and thus are of more 
therapeutic relevance than others of lower functional avidity.  
The differences observed in the functional avidities between clones of the same epitope 
specificity and HLA allele restriction could be related to variations in the levels of TCR 
expression. T cells with low surface TCR expression may not have been able to respond 




Alternatively, it has been previously reported that T cells expressing enhanced affinity 
TCRs have a direct influence on the strength of an immune response and thus functional 
avidity of a T cell (Thomas et al 2011). This means T cells with high affinity TCRs 
would recognise much lower levels of the PRS peptide epitope presented through MHC 
class II on target cells and still induce a robust immune response. 
Other factors to be considered include the efficiency of exogenous peptide epitope 
processing and presentation within the target cell, along with interactions between TCR 
and pMHC as a result of specific binding anchor residues. This would subsequently lead 
to more efficient binding kinetics and functional outputs of specific clonal populations. 
X-ray crystallography analysis of epitope specific CD4 T cell immune responses has 
reported the effects of exogenous peptide processing and presentation by MHC II 
molecules resulting in enhanced flexibility. These present peptides able to adopt a 
variety of conformational states, displaying amino acid side chains which promote 
better recognition and TCR binding interactions associated with more efficient immune 
responses (Pu et al 2002).  
Structural analysis of TCR binding to pMHC has further revealed the T cell coreceptor 
has implications on the sensitivity of immune responses with regards to functional 
avidity. In the context of CD8 T cell responses, studies have highlighted the influences 
of the CD8 co-receptor on association and dissociation rates, enhancing antigen 
recognition and binding efficiency particularly in T cells expressing low affinity TCRs, 
along with increasing the rate of subsequent intracellular activation processes induced 
by the TCR/CD3 complex (Artyomov et al 2010). However, the exact mechanisms by 




Importantly, within these peptide titration assays and the earlier screening assays, it was 
apparent that many of the CD4+ T cell clones could recognise the unmanipulated LCL 
target cell without the addition of cognate PRS epitope peptide. This is an important in 
vitro indication that such clones may be able to directly recognise EBV derived 
lymphoproliferations in vivo, and be of therapeutic benefit. Within the literature it is 
already apparent PRS specific CD4+ T cell clones are able to recognise and eliminate 
autologous LCL targets (Khanna et al 1997, Omiya et al 2002, Long et al 2005). We 
therefore investigated this further by assessing the efficiency of LCL recognition among 
these clones of known functional avidity and Vβ usage.  Previous work conducted by 
Omiya et al generated PRS specific clones, which similarly were able to recognise 
autologous unmanipulated LCL target, determined through IFNγ cytokine production. 
Though, these response levels were not compared to that of a maximal peptide-induced 
response (Omiya et al 2002). Further to this, work conducted by Long et al, 
investigating LCL recognition efficiency as a percentage of that seen in parallel against 
the same LCL target pre-loaded with optimal PRS epitope peptide, reported that PRS 
specific CD4+ T cell clones of varying MHCII restriction had percentage LCL 
recognition efficiencies ranging from 1-35%. In particular, HLA DR7 restricted clones 
had an efficiency of 15% (Long et al 2005). However, these earlier studies assessed a 
limited number of clones, with unknown TCRVβ usage. Therefore, we sought to expand 
on these previous findings by analysing the function of our T cell clones with known Vβ 
usage, in order to determine if there was an association between the two factors. 
Here, we found that the 7 PRS specific CD4+ T cell clones analysed from donor 1 all 
had an efficiency of LCL recognition above 10%, and 3 clones, in particular, had 




Surprisingly, the clones generated from donor 2 all had much lower percentage 
recognition efficiencies with only one showing an efficiency above 10%.  
Importantly, the differences in LCL recognition between clones within each donor were 
consistent with the pattern of functional avidities previously determined in the peptide 
titration assays. Predominantly, within donor 1, the PRS-specific clones with high 
functional avidity had increased ability to recognise physiological levels of PRS 
epitope, endogenously processed and presented by autologous LCLs, as observed 
through the higher LCL recognition efficiencies. Many investigators have similarly 
demonstrated this correlation between T cell avidity and target recognition of T cell 
populations that are able to recognise virally infected antigen presenting cells, murine 
models and human cancer cell targets (Dudeley et al 1999, Zeh et al 1999). 
However, these results cannot be solely explained by the correlation observed with T 
cell clonal functional avidities. Evidence of this has been reported through clinical trials, 
in which high avidity T cells, specific for the tumour associated antigen, Her-2/neu+ 
were unable to recognise tumour cells despite showing response towards peptide loaded 
targets (Zaks et al 1998, Knutson et al 2002). These conflicting results emphasise the 
complexity of the relationship between avidity and target cell recognition, with many 
other presently unknown underlying factors in need of investigation.  
The level of LCL recognition may in fact be influenced by the degree of PRS epitope 
presentation on the autologous unmanipulated LCL surface. This could therefore be 
again linked to efficiency of intracellular processing of the cognate PRS peptide by the 





To prevent bias arising due to this, within this study we conducted the assays on all 
clones in parallel, and performed three replicates to generate a mean. Furthermore, all 
assays used the same number of autologous HLA matched LCL and T cells per well, 
and further equal numbers of control HLA mismatched LCLs. 
The observed ability to successfully recognise LCL targets, which represent EBV 
infected B cell blasts, provides support for the possibility that EBV epitope specific 
CD4+ T cells, circulating within the peripheral blood of seropositive carriers, may 
display comparable properties, in vivo and could be further investigated for other direct 
effector mechanisms and functional relationships.  The relative sensitivity of a T cell 
towards an antigen target, thus may influence its subsequent ability to recognise cancer 
cells, emphasising the importance of high avidity T cells in anti-tumour immunity and 
subsequent selection for adoptive immunotherapeutic applications.   
 
4.4 TCRVβ usage influences on T cell function  
Our main motivation for this work was to address the potential relationship between Vβ 
usage and the function of epitope specific CD4+ T cell clones. The ability to determine 
TCRs from defined clonal populations, conferring the greatest functional output with 
regards to activation, proliferation, and target cell lysis is of key importance for future 
therapeutic application to be successful. However, the biological impact of TCR 
repertoire usage within epitope specific T cell populations, is still yet to be investigated 
fully.  
From our analysis, when comparing clones of the same Vβ usage, for example clone 99 




of 5nM and percentage LCL recognition efficiencies of 21% and 27%.  However, other 
clones from donor 1 also using Vβ1, had much lower functional avidities and 
percentage LCL recognition efficiencies. For example, clone 83 using Vβ1 had a 
functional avidity of 30nM and an LCL recognition efficiency of 18%. Furthermore, 
within donor 1 high avidities and LCL recognition efficiencies were apparent in clones 
using differing Vβs including clone 2 and 21 which both showed usage of Vβ21.3. 
These findings are interesting, as despite the differences in Vβ expression between 
clones from the same individual, structural conservation of defined TRBV genes and 
CDR3 motifs between clones of similar functional capacity may still have been 
apparent. TCR repertoire diversity is now known to contribute significantly towards 
immune defence mechanisms; providing a large initial pool of clonal populations, with 
differing TCRVβ from which the most efficient T cells can then be selected for (InYong 
Song et al 2017). Thus, this would imply that within epitope specific CD4+ T cell 
populations, the combination of overall diversity and finite structural similarities in 
specific clonal populations is of key importance in an efficient and robust immune 
response. 
To determine whether fine differences in the CDR3 binding region of the TCRs were 
responsible for the observed differing functional properties of the PRS-specific CD4+ T 
cell clones, we went on to sequence the alpha and beta chains of the TCRs from the 
clones isolated from donor 1 that used Vβ1 and Vβ21.3. Structural and sequence 
analysis has reported, in the context of chronic CMV infection in healthy individuals, 
extreme conservation of T cell receptor usage in both TCRα and TCRβ chains of 
epitope specific cytotoxic CD4+ T cell clones displaying high functional avidity, 




suggests that during chronic viral infections, clonal selection occurs upon initial epitope 
recognition. Subsequent repeated exposure of lymphocytes to the same antigen derived 
epitope may thus result in immunodominance of specific TCR gene sequences 
conferring cells of the greatest cytotoxic potential. 
From our own analysis performed, despite successful amplification of PCR products for 
both TCRα and TCRβ chains of all clones assessed, the sequencing data was 
inconclusive. This may have been due to the presence of other cells carrying none 
specific TCRs, for example if the T cell clones were not truly monoclonal or if feeder 
cells were still remaining within the cultures after re-stimulation. Unfortunately, due to 
the limited time availability and substantial cost of TCR isolation and sequencing, 
subsequent TCRseq replicates could not be performed and it was not possible to draw 
definite conclusions. A full analysis of whether there are similarities in the CDR3 
motifs of the TCRs of the clones with similar functional parameters and the 
same/different Vβ usage remains to be performed.  
There have been earlier attempts to characterise the function of epitope-specific CD4+ 
T cells with distinct TCR usage, however this analysis was based on the functional 
interactions of T cell receptors contacting different residues located within the target 
peptide, and thus binding interactions rather than differences in TCR sequence (Pu et al 
2002). Nevertheless, these investigations do open up the possibility to explore 
influences other than the TCR structural components, such as the conformational 
recognition of peptide by TCR contact residues.  Further detailed structural information 
is therefore required to determine if initial TCR-pMHC binding interactions, and the 
components within them, do in fact have any significant influence on the functioning of 




More recently, a study investigating influenza virus epitope specific CD8+ T cell 
immune responses has shown that a highly diverse repertoire, including both dominant 
public TCRs and a variety of private structural CDR3 components, may be key to 
successful antigen recognition and effective immune responses. These diverse TCR 
patterns have been suggested to be crucial to protect against individual clonal loss, 
thereby ensuring the maintenance of an antigen-specific effector memory T cell pool 
(InYoung Song et al 2017). Based on these findings it was proposed that differing 
sequences may consequentially activate downstream effector mechanisms differently, 
resulting in heterogenous functioning of different T cells (InYoung Song et al 2017).  
Recent work has attempted to build on these ideas integrating information about TCR 
sequence specificity with multiparametric phenotypic analysis of bulk T cells at a single 
cell level, in the context of cancers such as colorectal carcinoma (Han et al 2014). It was 
reported that similarities were apparent in cells displaying the same TCR sequence and 
transcription factor regulating cellular differential status. However, there was no 
indication of TCR structure influencing immune response efficiency, sensitivity, or 
target cell elimination. Further to this, it did not have the availability of MHC tetramer 
reagents and thus identification of epitope specificity and HLA restriction was not 
achieved.  
Gros and colleagues additionally reported within melanoma patients tumour-infiltrating 
PD-1 neoantigen specific CD8+ T cell populations proved a valuable source in 
identification of TCRs with therapeutic potential (Gros et al 2014). Despite these 
conclusions made, to what extent these TCRs represented T cells of the best avidity was 




To date no conclusive evidence has been made into the influences of TCRVβ usage on 
cytotoxic capacity of anti-viral and anti-tumour T cell immune responses. From our 
knowledge this is the first exploration of the TCRVβ usage of human CD4+ T cell 
clones of known epitope specificity and MHCII restriction isolated, ex vivo. The 
biological basis for this distinct TCR repertoire usage and its association with cellular 
functional output still remains unclear. Thus, deeper insights into the mechanisms 
regulating this, are required to improve understanding of T cell immunology and further 
help to identify optimal TCRs for future targeted immunotherapies.  
4.5 Future work 
To generate more in depth knowledge regarding the link between TCR usage and 
functioning of PRS specific CD4+ T cells further work is needed. Unfortunately, the 
TCR sequencing data produced from this study was inconclusive. With additional 
troubleshooting, both the alpha and beta chain gene sequences could be successfully 
identified meaning more structural comparisons between the PRS specific clones could 
be made. In the context of viral infection and cancer, TCR sequencing has recently 
provided useful insights into the T cell repertoire within both diseased and healthy 
individuals. Previous studies have reported homology of conserved TRAV, TRBV 
genes and amino acid CDR3 motifs, between HLA matched healthy viral carriers and 
cancer patients, targeting the same peptide epitope (Chrompton et al 2008). 
Identification of public T cell clonotypes, shared between HLA matched healthy and 
diseased individuals, is essential in the development of biomarkers and diagnostics for 
various infectious and neoplastic diseases. As a technique, antigen receptor profiling 
further provides the potential to develop immunotherapies utilised in the reconstitution 




as GvHD.  TCR gene sequences conferring the best functional properties, could thus be 
isolated and assessed for potential gene modification of subsequent transfused T cell 
populations.   
The initial monomeric engagement between the TCR and its pMHC complex plays a 
critical role in determining the activity of a T cell. The binding property of TCR 
affinity, associated with this interaction, has been correlated to more efficient cellular 
activation by lower concentrations of cognate peptide and an increase in T cell 
functional capacity (Holler et al 2003). This has been assessed through measuring the 
dissociation constant rate (Koff) of soluble TCRs through surface plasmon resonance 
(SPR).  SPR is an effective biosensor tool for quantitative characterisation and real-time 
information on the course of reversible interactions between biological macromolecules. 
In the context of viral infection, interactions with longer dissociation kinetics/slower 
koff rates have been previously reported to confer significantly better protection than T 
cell populations with fast koff rates (Nauerth et al 2013). However, this rate needs to be 
fast enough to prevent detrimental effects on subsequent serial triggering of multiple 
other TCRs to a single pMHC. Thus, being able to pinpoint optimal dissociation time 
for maximal T cell activation, is needed to decipher the exact relationship between the 
kinetics of TCR-pMHC binding interactions and functional output of a cell. 
There is some evidence achieved through thermodynamic analysis, to further suggest 
that conformational plasticity, during TCR-pMHC initial binding, may also be a factor 
determining the strength of this TCR binding parameter and overall T cell activity 




What still remains unclear is why physiological TCR affinities have evolved to be 
relatively low. It has been proposed that the immune system sacrifices TCRs of high 
affinity, which could mediate greater functional activity in order to maintain a TCR 
repertoire diverse enough to combat a wide range of different potential antigens 
preventing clonal deletion of both epitope specific CD4+ and CD8+ T cells.  Ultimately, 
future work is required to underpin the exact causative agent promoting higher affinity 
TCRs from these complex binding interactions.  
Once the TCRs have been isolated from our PRS-specific T cell clones, similar 
evaluation of these TCR-pMHC binding kinetics, on a single cell level, could be 
achieved in order to provide further information regarding the influence of TCR binding 
affinity to the overall difference in function of CD4+ T cell clones with different 
TCRVβ usage and functional avidities.   
The direct effector mechanisms of epitope specific T cells are paramount for 
establishment of an effective immune response. Phenotypical characterisation of total 
CD4+ T cell populations has reported low frequencies of cells expressing many of the 
surface markers required for cytotoxic killing (Appay et al 2002). However, the 
presence of such molecules does not always result in the induction of killing 
mechanisms after cells are challenged with their cognate antigen.  The use of killing 
assays to evaluate this further, has shown promising results. In the context of EBV, 
previous studies have investigated the cytotoxic potential of EBV-specific CD4+ T cells 
and their ability to inhibit target cell outgrowth, in vitro (Munz et al 2000, Nikiforow et 
al 2003, Long et al 2005). It has been reported that the inhibition of LCL growth 
correlates with cytotoxic activity, and CD4+ T cell clones with high LCL recognition 




cytotoxic capacity of our PRS-specific clones of known Vβ usage, to determine whether 
this also correlates with their functional avidity and LCL recognition efficiency. This 
would enable determination of individual clonotypes with the most therapeutic 
relevance based on direct elimination of EBV infected cells and inhibition of cancer cell 
outgrowth. These features within anti-viral and anti-tumour immune responses are 
paramount for subsequent adoptive immunotherapeutic strategies to be effective. 
 
4.6 Conclusions 
In summary, our results have demonstrated that HLADR7 restricted CD4 T cell clones 
specific for the immunodominant EBNA2, PRS epitope comprise TCRs with a number 
different TCR usages, including common use of distinct Vβs. We have further shown 
through functional analysis of clones with known Vβ usage, that a range of functional 
avidities are apparent among the clones of the same and different Vβ usages, within 
different healthy individuals. Those T cells exhibiting better functional avidity for their 
cognate peptide similarly display higher levels of percentage recognition efficiency of 
autologous EBV-infected LCL targets.  The finding thus indicate that distinct TCR 
usage may contribute to differences in T cell function, and that TCRs used 
therapeutically should be carefully selected based on their preferential properties. This 
study should enable similar analysis on other viral systems and lead to research in 
identifying immunodominant TCR sequences and motifs of epitope specific T cell 
clonotypic populations inducing the most robust immune responses. Similarly, 
identifying the mechanisms by which epitopes of interest access the MHC class II 




efficient recognition, binding and high avidity responses, represents a significant 
priority for ongoing future work.  
The work performed here provides a useful model for harnessing and amplifying 
epitope specific CD4+ T cell immune responses. From a clinical standpoint, this has 
important implications for the development of effective and viable TCR gene transfer 
immunotherapies, targeting a variety of cancers presenting antigens through MHC class 
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